| Title of Invention | SULFONAMIDE COMPOUNDS HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY |
|---|---|
| Abstract | The present invention provides an sulfonamide derivative having DP receptor antagonistic activity and a pharmaceutical composition comprising the said compound as an active ingredient, and further a therapeutic agent for treating allergic diseases. A compound of the general formula (II): wherein the ring A is an aromatic carbocyclic ring etc.; the ring B is a nitrogen-containing non-aromatic heterocyclic ring etc.; the ring C is an aromatic carbocyclic ring etc.; Rl is carboxy etc.; R2 is independently a halogen atom etc.; R3 is optionally substituted alkyloxy etc.; R4 is independently a halogen atom etc.; R5 is independently optionally substituted alkyl etc.; M is sulfonyl etc.; Y is a single bond etc.; LI is a single bond etc.; L2 is a single bond etc.; k is 0, 1, 2, 3 or 4; n is 0, 1 or 2; and q is 0, 1, 2 or 3; provided that a) k is not 0 when the ring B is a 6-membered nitrogen-containing heterocyclic ring containing one or two nitrogen atom(s) and the ring C is a benzene ring, etc.; a pharmaceutically acceptable salt or a hydrate thereof. |
| Full Text | SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY TECHNICAL FIELD This invention relates to a sulfonamide derivative having DP receptor antagonistic activity and a medicinal use thereof. BACKGROUND ART Prostaglandin D2(PGD2) is a metabolic product of arachidonic acid through PGG2 and PGH2, and known to have various potent physiological activities. For example, in non-patent literature 1 it is described that PGD2 is involved in sleeping and secretion of hormones in central nervous system, and in inhibiting activity of platelet aggregation, contraction of bronchial smooth muscle, vasodilation and constriction of a blood vessel etc. in peripheral system. Moreover, PGD2 is considered to be involved in forming pathological condition of an allergic disease such as bronchial asthma since it is a major metabolic product of arachidonic acid produced from a mast cell, and has a potent bronchoconstricting effect, causing an increase of vascular permeability and migration of inflammatory cell such as eosinophils. A DP receptor (also called DPI receptor) or CRTH2 receptor(also called DP2 receptor) is known as a receptor of PGD2. A phenylacetic acid derivative having a DP receptor antagonistic activity is disclosed in Patent literature 1, a sulfonamide derivative having a CRTH2 receptor antagonistic activity is disclosed in Patent literature 2 and a phenoxyacetic acid derivative having a CRTH2 receptor antagonistic activity is disclosed in Patent literatures 3-6. Also, sulfonamide derivatives having an activity other than the PGD2 receptor antagonistic activity are disclosed in Patent literatures 7-12 and Nonpatent literatures 2-3. Patent literature 1: WO 2003/078409 Pamphlet Patent literature 2: WO 2003/097598 Pamphlet Patent literature 3: WO 2004/089884 Pamphlet Patent literature 4: WO 2004/089885 Pamphlet Patent literature 5: WO 2005/106302 Pamphlet Patent literature 6: WO 2006/056752 Pamphlet Patent literature 7: WO 1993/012086 Pamphlet Patent literature 8: WO 2004/073606 Pamphlet Patent literature 9: EP 76996A Pamphlet Patent literature 10: WO 2006/059801 Pamphlet Patent literature 11: JP 3-275678A Pamphlet Patent literature 12: JP 3-275679A Pamphlet Non patent literature 1: Pharmacol. Rev., 1994, Vol.46, p.205-22 Non patent literature 2: Chem. & Pharm. Bull., 1994, Vol.42, p.521-29 Non patent literature 3: Chem. SE Pharm. Bull., 2000, VoL48, p. 1978-85 DISCLOSURE OF INVENTION PROBLEM TO BE SOLVED The present invention provides a sulfonamide derivative having DP receptor antagonistic activity and a pharmaceutical composition comprising the said compound as an active ingredient. The said pharmaceutical composition is useful as a therapeutic agent for treating allergic diseases. MEANS FOR SOLVING PROBLEM The present inventors have found that the sulfonamide derivative shown below has a potent DP receptor antagonistic activity and the pharmaceutical composition comprising the said compound as an active ingredient is useful as a therapeutic agent for treating allergic diseases. The present invention relates to 1) a PGD2 receptor antagonist comprising a compound of the general formula (I): R1 is hydroxyalkyl, carboxy, alkyloxycarbonyl, optionally substituted carbamoyl, cyano or a carboxy equivalent; R2 is independentiy a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, hydroxy, optionally substituted alkyloxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted cycloalkyloxy, optionally substituted cycloalkenyloxy, mercapto, optionally substituted alkylthio, optionally substituted alkenylthio, optionally substituted alkynylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted alkylsulfonyloxy, optionally substituted cycloalkylthio, optionally substituted cycloalkylsulfinyl, optionally substituted cycloalkylsulfonyl, optionally substituted cycloalkylsulfonyloxy, optionally substituted cycloalkenylthio, optionally substituted cycloalkenylsulfinyl, optionally substituted cycloalkenylsulfonyl, optionally substituted cycloalkenylsulfonyloxy, optionally substituted amino, acyl, optionally substituted alkyloxycarbonyl, optionally substituted alkenyloxycarbonyl, optionally substituted alkynyloxycarbonyl, optionally substituted aryloxycarbonyl, optionally substituted carbamoyl, optionally substituted sulfamoyl, cyano, nitro, optionally substituted aiyl, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted arylsulfinyl, optionally substituted arylsulfonyl, optionally substituted arylsulfonyloxy, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heteroarylthio, optionally substituted heteroarylsulfinyl, optionally substituted heteroarylsulfonyl, optionally substituted heteroaiylsulfonyloxy or an optionally substituted non-aromatic heterocyclic group; R3 is a hydrogen atom, optionally substituted alkyloxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted cycloalkyloxy, optionally substituted cycloalkenyloxy, optionally substituted aryloxy, optionally substituted heteroaryloxy, optionally substituted alkylthio, optionally substituted alkenylthio, optionally substituted alkynylthio, optionally substituted cycloalkylthio, optionally substituted cycloalkenylthio, optionally substituted arylthio or optionally substituted heteroarylthio; R4 is independentiy a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, hydroxy, optionally substituted alkyloxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted cycloalkyloxy, optionally substituted cycloalkenyloxy, mercapto, optionally substituted alkylthio, optionally substituted alkenylthio, optionally substituted alkynylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted alkylsulfonyloxy, optionally substituted cycloalkylthio, optionally substituted cycloalkylsulfinyl, optionally substituted cycloalkylsulfonyl, optionally substituted cycloalkylsulfonyloxy, optionally substituted cycloalkenylthio, optionally substituted cycloalkenylsulfinyl, optionally substituted cycloalkenylsulfonyl, optionally substituted cycloalkenylsulfonyloxyj optionally substituted amino, acyl, optionally substituted alkyloxycarbonyl, optionally substituted alkenyloxycarbonyl, optionally substituted alkynyloxycarbonyl, optionally substituted axyloxycarbonyl, optionally substituted carbamoyl, optionally substituted sulfamoyl, cyano, nitro, optionally substituted aryl, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted arylsulfinyl, optionally substituted arylsulfonyl, optionally substituted arylsulfonyloxy, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heteroarylthio, optionally substituted heteroarylsulfinyl, optionally substituted heteroarylsulfonyl, optionally substituted heteroaiylsulfonyloxy or an optionally substituted non-aromatic heterocyclic group; R5 is independently a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted alkyloxy, oxo, optionally substituted aiyl, optionally substituted heteroaryl or an optionally substituted non-aromatic heterocyclic group; M is carbonyl or sulfonyl; Y is a single bond, optionally substituted alkylene optionally containing one or two heteroatom(s), an oxygen atom, a sulfur atom or -N(R6)-; L1, L2 and L3 are independently a single bond, optionally substituted alkylene optionally containing one or two heteroatom(s), optionally substituted alkenylene optionally containing one or two heteroatom(s), optionally substituted alkynylene optionally containing one or two heteroatom(s) or -N(R7)-; R6 and R7 are independently a hydrogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, acyl, optionally substituted alkyloxy, optionally substituted aryl, optionally substituted heteroaryl or an optionally substituted non-aromatic heterocyclic group; kis 0, 1, 2, 3 or 4; n is 0, 1 or 2; and q is 0, 1, 2 or 3; provided that a) k is not 0 when the ring B is a 6-membered nitrogen-containing heterocyclic ring containing one or two nitrogen atom(s), and the ring C is a benzene ring, b) the ring C is not an indole ring or an azaindole ring, c) R1 is not carboxy when the ring C is a benzene ring, -L^- is -(O-alkylene)-, and the substituting position of L3 and Y is an ortho-position each other in the ring C, and d) the substituting position of L3 and Y is not a para-position in the ring C when the ring B is a thiazolidine ring and the ring C is a benzene ring; a pharmaceutically acceptable salt or solvate thereof as an active ingredient, 2) a PGD2 receptor antagonist of 1) wherein R1 is carboxy and -L3- is -(O-optionally substituted alkylene)-, 3) a PGD2 receptor antagonist of 1) or 2) wherein the ring C is a benzene ring or a pyridine ring, 4) a PGD2 receptor antagonist of any of 1) to 3) wherein R3 is optionally substituted alkyloxy or optionally substituted alky'lthio, 5) a PGD2 receptor antagonist of any of 1) to 4) wherein M is sulfonyl, 6) a PGD2 receptor antagonist of any of 1) to 5) wherein M is sulfonyl, L^ is a single bond and L2 is a single bond, 7) a PGD2 receptor antagonist of any of 1) to 6) wherein Y is a single bond, 8) a PGD2 receptor antagonist of any of 1) to 7) wherein R2 is a halogen atom, optionally substituted alkyl, optionally substituted alkyloxy, optionally substituted amino, optionally substituted carbamoyl, optionally substituted aryl, optionally substituted heteroaryl or an optionally substituted non-aromatic heterocyclic group, and k is 1 or 2, 9) a PGD2 receptor antagonist of any of 1) to 7) wherein R2 is a halogen atom., optionally substituted amino, optionally substituted carbamoyl, optional!}^ substituted aryl, optionally substituted heteroaryl or an optionally substituted non-aromatic heterocyclic group, and k is 1 or 2, heterocyclic ring; the ring B is a nitrogen-containing non-aromatic heterocyclic ring or a nitrogen-containing aromatic heterocyclic ring; the ring C is an aromatic carbocyclic ring or an aromatic heterocyclic ring; R1 is hydroxyalkyl, carboxy, alkyloxycarbonyl, optionally substituted carbamoyl, cyano or a carboxy equivalent; R2 is independently a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, hydroxy, optionally substituted alkyloxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy optionally substituted cycloalkyloxy, optionally substituted cycloalkenyloxy, mercapto, optionally substituted alkylthio, optionally substituted alkenylthio, optionally substituted alkynylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted alkylsulfonyloxy, optionally substituted cycle alkylthio, optionally substituted cycloalkylsulfinyl, optionally substituted cycloalkysulfonyl, optionally substituted cycloalkylsulfonyloxy, optionally substituted cycloalkenylthio, optionally substituted cycloalkenylsulfinyl, optionally substituted cycloalkenylsulfonyl, optionally substituted cycloalkenylsulfonyloxy, optionally substituted amino, acyl, optionally substituted alkydoxycarbonyl, optionally substituted alkenyloxycarbonyl, optionally substituted alkynyloxycarbonyl, optionally substituted aryloxycarbonyl, optionally substituted carbamoyl, optionally substituted sulfamoyl, cyano, nitro, optionally substituted aryl, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted arylsulfinyl, optionally substituted arylsulfonyl, optionally substituted arylsulfonyloxy, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heteroarylthio, optionally substituted heteroarylsulfinyl, optionally substituted heteroarylsulfonyl, optionally substituted heteroarylsulfonyloxy or an optionally substituted non-aromatic heterocyclic group; R3 is a hydrogen atoms, optionally substituted alkyloxy, optionally substituted alkenyloxy optionally substituted alkynyloxy, optionally substituted cycloalkyloxy, optionally substituted cycloalkenyloxy, optionally substituted aryloxy, optionally substituted heteroaryloxy, optionally substituted alkylthio, optionally substituted alkenylthio, optionally substituted alkynylthio, optionally substituted cycloalkylthio, optionally substituted cycloalkenylthio, optionally substituted arylthio or optionally substituted heteroarylthio; R4 is independentiy a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, hydroxy, optionally substituted alkyloxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted cycloalkyloxy, optionally substituted cycloalkenyloxy, mercapto, optionally substituted alkylthio, optionally substituted alkenylthio, optionally substituted alkynylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted alkylsulfonyloxy, optionally substituted cycloalkylthio, optionally substituted cycloalkylsulfinyl, optionally substituted cycloalkylsulfonyl, optionally substituted cycloalkylsulfonyloxy, optionaly substituted cycloalkenylthio, optionally substituted cycloalkenylsulfinyl, optionally substituted cycloalkenylsulfonyl, optionally substituted cycloalkenylsulfonyioxy, optionally substituted amino, acj'-l, optionally substituted alk3doxycarbon3d, optionallj^ substituted alkenyloxycarbonyl, optionally substituted alkynyloxycarbonyl, optionally substituted aryloxycarbonyl, optionally substituted carbamoyl, optionally substituted sulfamoyl, cyano, nitro, optionally substituted aiyl, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted arylsulfinyl, optionally substituted arylsulfonyl, optionally substituted arylsulfonyloxy, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heteroarylthio, optionally substituted heteroarylsulfinyl, optionally substituted heteroarylsulfonyl, optionally substituted heteroarylsulfonyloxy or an optionally substituted non-aromatic heterocyclic group; R5 is independentiy a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted alkyloxy, oxo, optionally substituted aiyl, optionally substituted heteroaryl or optionally substituted non-aromatic heterocyclic group; M is carbonyl or sulfonyl; Y is a single bond, optionally substituted alkylene optionally containing one or two heteroatom(s), an oxygen atom, a sulfur atom or -N(R6)-; L1, L2 and L3 are independentiy a single bond, optionally substituted alkylene optionally containing one or two heteroatom(s), optionally substituted alkenylene optionally containing one or two heteroatom(s), optionally substituted alkynylene optionally containing one or two heteroatom(s) or -NfR*^)-; R6 and R7 are independentiy a hydrogen atom, optionally substituted alkyl optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, acyl, optionally substituted alkyloxy, optionally substituted aryl, optionally substituted heteroaryl or an optionally substituted non-aromatic heterocyclic group; kis 0, 1, 2, 3 or 4; n is 0, 1 or 2; and q is 0, 1, 2 or 3; provided that a) k is not 0 when the ring B is a 5-membered nitrogen-containing heterocyclic ring containing one or two nitrogen atom(s), and the ring C is a benzene ring, b) the ring C is not an indole ring or an azaindole ring, c) Y, L1 and L2 are single bonds, the ring B is piperazine ring and R3 is C2-C4 alkyloxy when the ring C is a benzene ring, -L3- is -(O-alkylene)-, the substituting position of L3 and Y is an ortho-position each other in the ring C and R1 is carboxy, d) the substituting position of L3 and Y is not a a pharmaceutically acceptable salt or solvate thereof, 15) a compound of 14) wherein R1 is carboxy and -L3- is -(O-optionally substituted alkylene)-; a pharmaceutically acceptable salt or solvate thereof, 16) a compound of 14) or 15) wherein the ring C is a benzene ring or a pyridine ring; a pharmaceutically acceptable salt or solvate thereof, 17) a compound of any of 14) to 15) wherein R3 is optionally substituted alkyloxy or optionally substituted alkylthio; a pharmaceutically acceptable salt or solvate thereof, 18) a compound of any of 14) to 17) wherein M is sulfonyl; a pharmaceutically acceptable salt or solvate thereof, 19) a compound of any of 14) to 17) wherein M is sulfonyl, L1 is a single bond and L2 is a single bond, a pharmaceutically acceptable salt or solvate thereof, 20) a compound of any of 14) to 19) wherein Y is a single bond; a pharmaceutically acceptable salt or solvate thereof, 21) a compound of any of 14) to 20) wherein R2 is a halogen atom, optionally substituted alkyl, optionally substituted alkyloxy, optionally substituted amino, optionally substituted carbamoyl, optionally substituted aryl, optionally substituted heteroaryl or an optionally substituted non-aromatic heterocyclic group, and k is 1 or 2; a pharmaceutically acceptable salt or solvate thereof, 22) a compound of any of 14) to 20) wherein R^ is a halogen atom, optionally substituted amino, optionalty substituted carbamoyl, optionally substituted aryl, optionally substituted heteroaryl or an optionally substituted non-aromatic heterocyclic group, and k is 1 or 2; a pharmaceutically acceptable salt or solvate thereof, 23) a compound of any of 14) to 22) wherein R4 is a halogen atom, optionally substituted alkyl or optionally substituted alkyioxy, and q is 0 or 1, a pharmaceutically acceptable salt or solvate thereof, 24) a compound of any of 14) to 23) wherein the substituting position of Y and L3 is a meta-position in the ring C, a pharmaceutically acceptable salt or solvate thereof, 25) a com.pound of the general formula (III): wherein the ring D is a benzene ring, a naphthalene ring, a 2-pyridone ring, a pyridine ring, a benzoxajzolone ring, a benzoxadinone ring or a benzimidazole ring; R1 is hydroxyalkyl, carboxy, alkyloxycarbonyl, optionally substituted carbamoyl, cyano or a carboxy equivalent; R2 is independently a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, hydroxy, optionally substituted alkyloxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy optionally substituted cycloalkyloxy, optionally substituted cycloalkenyloxy, mercapto, optionally substituted alkylthio, optionally substituted alkenylthio, optionally substituted alkynylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted alkylsulfonyloxy, optionally substituted cycloalkylthio, optionally substituted cycloalkylsulfinyl, optionally substituted cycloalkylsulfonyl, optionally substituted cycloalkylsulfonyloxy, optionally substituted cycloalkenylthio, optionally substituted cycloalkenylsulfinyl, optionally substituted cycloalkenylsulfonyl, optionally substituted cycloalkenylsulfon34oxy, optionally substituted amino, acyl, optionally substituted alkyloxycarbonyl, optionally substituted alkenyloxycarbonyl, optionally substituted alkjniyloxycarbonyl, optionally substituted aryloxycarbonyl, optionally substituted carbamoyl, optionally substituted sulfamoyl, cyano, nitro, optionally substituted aryl, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted arylsulfinyl, optionally substituted arylsulfonyl, optionally substituted arylsulfonyloxy optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heteroarylthio, optionally substituted heteroarylsulfinyl, optionally substituted heteroarylsulfonyl, optionally substituted heteroarylsulfonyloxy or an optionally substituted non-aromatic heterocyclic group; R3 is optionally substituted C1-C6 alkyloxy, optionally substituted C2-C6 alkenyloxy, optionally substituted C2-C6 alkynyloxy, optionally substituted C3-C6 cycloalkyloxy, optionally substituted C3-C6 cycloalkenyloxy, optionally substituted aryloxy, optionally substituted heteroaryloxy, optionally substituted C1-C6 alkylthio, optionally substituted C2-C5 alkenylthio, optionally substituted C2-C6 alkynylthio, optionally substituted C3-C6 cycloalkylthio, optionally substituted C3-C5 cycloalkenylthio, optionally substituted arylthio or optionally substituted heteroarylthio; R4 is independentiy a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, hydroxy, optionally substituted alkyloxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted cycloalkyloxy, optionally substituted cycloalkenyloxy, mercapto, optionally substituted alkylthio, optionally substituted alkenylthio, optionally substituted alkynylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted alkylsulfonyloxy, optionally substituted cycloalkylthio, optionally substituted cycloalkylsulfinyl, optionally substituted cycloalkylsulfonyl, optionally substituted cycloalkylsulfonyloxy, optionally substituted cycloalkenylthio, optionally substituted cycloalkenylsulfinyl, optionally substituted cycloalkenylsulfonyl, optionally substituted cycloalkenylsulfonyloxy, optionally substituted amino, acyl, optionally substituted alkyloxycarbonyl, optionally substituted alkenyloxycarbonyl, optionally substituted alkynyloxycarbonyl, optionally substituted aryloxycarbonyl, optionally substituted carbamoyl, optionally substituted sulfamoyl, cyano, nitro, optionally substituted aryl, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted arylsulfinyl, optionally substituted aiylsulfonyl, optionally substituted arylsulfonyloxy, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heteroarylthio, optionally substituted heteroarylsulfinyl, optionally substituted heteroarylsulfonyl, optionally substituted heteroarylsulfonyloxy or optionally substituted non-aromatic heterocyclic group; R5 is independently a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted alkyloxy, oxo, optionally substituted aryl, optionally substituted heteroaryl or an optionally substituted non-aromatic heterocyclic group; M is carbonyl or sulfonyl; L3 is independently a single bond, optionally substituted alkylene optionally containing one or two heteroatom(s), optionally substituted alkenylene optionally containing one or two heteroatom(s), optionally substituted alkynylene optionally containing one or two heteroatom(s) or -N(R'^)-; R7is hydrogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, acyl, optionally substituted alkyloxy, optionally substituted aryl, optionally substituted heteroaryl or an optionally substituted non-aromatic heterocyclic group; Y is a single bond or optionally substituted alkylene optionally containing one or two heteroatom(s); Z is CH, C(R4) or N; n is 0, 1 or 2; p s 1, 2, 3 or 4; and q is 0, 1, 2 or 3; provided that R1 is not carboxy when the ring D is a benzene ring, -L3- is -(O-alkylene)-, and the substituting position of L3 and Y is an ortho-position in the ring D; a pharmaceutically acceptable salt or hydrate thereof, 26) a compound of 25) wherein R1 is carboxy and -L3- is -(O-optionally substituted alkylene)-; a pharmaceutically acceptable salt or solvate thereof, 27) a compound of 25) or 26) wherein the ring D is a benzene ring or a pyridine ring; a pharmaceutically acceptable salt or solvate thereof, 28) a compound of any of 25) to 27 wherein R3 is optionally substituted Cl- C6 alkyloxyl, or optionally substituted C1-C5 alkylthio; a pharmaceutically acceptable salt or solvate thereof, 29) a compound of any of 25) to 28) wherein M is sulfonyl; a pharmaceutically acceptable salt or solvate thereof, 30) a compound of any of 25) to 29) wherein Y is a single bond; a pharmaceutically acceptable salt or solvate thereof, 31) a compound of any of 25) to 30) wherein R2 is a halogen atom, optionally substituted alkyl, optionally substituted alkyloxy, optionally substituted amino, optionally substituted carbamoyl, optionally substituted aryl, optionally substituted heteroaryl or an optionally substituted non-aromatic heterocyclic group, and p is 1 or 2; a pharmaceutically acceptable salt or solvate thereof, 32) a compound of any of 25) to 31) wherein R2 is a halogen atom, optionally substituted amino, optionally substituted carbamoyl, optionally substituted aryl, optionally substituted heteroaryl or an optionally substituted non-aromatic heterocyclic group, and p is 1 or 2; a pharmaceutically acceptable salt or solvate thereof, 33) a compound of any of 25) to 32) wherein R4 is a halogen atom, optionally substituted alkyl or optionally substituted alkyloxy, and q is 0 or 1, a pharmaceutically acceptable salt or solvate thereof, 34) a compound of any of 25) to 33) wherein the substituting position of Y and L3 is a meta-position in the ring D, a pharmaceutically acceptable salt or solvate thereof, 35) a compound of the general formula (IV): R1 is hydroxyalkyl, carboxy, alkyloxycarbonyl, optionally substituted carbamoyl, cyano or a carboxy equivalent; R2 is independently a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, hydroxy, optionally substituted alkyloxy optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted cycloalkyloxy, optionally substituted cycloalkenyloxy, mercapto, optionally substituted alkylthio, optionally substituted alkenylthio, optionally substituted alkynylthio, optionally substituted alkylsulfmyl, optionally substituted alkylsulfonyl, optionally substituted alkylsulfonyloxy, optionally substituted cycloalkylthio, optionally substituted cycloalkylsulfmyl, optionally substituted cycloalkylsulfonyl, optionally substituted cycloalkylsulfonyloxy, optionally substituted cycloalkenylthio, optionally substituted cycloalkenylsulfmyl, optionally substituted cycloalkenylsulfonyl, optionally substituted cycloalkenylsulfonyloxy, optionally substituted amino, acyl, optionally substituted alkyloxycarbonyl, optionally substituted alkenyloxycarbonyl, optionally substituted alkynyloxycarbonyl, optionally substituted aryloxycarbonyl, optionally substituted carbamoyl, optionally substituted sulfamoyl, cyano, nitro, optionally substituted aryl, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted arylsulfinyl, optionally substituted arylsulfonyl, optionally substituted arylsulfonyloxy, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heteroarylthio, optionally substituted heteroarylsulfinyl, optionally substituted heteroarylsulfonyl, optionally substituted heteroarylsulfonyloxy or an optionally substituted non-arormatic heterocyclic group; R3 is optionally substituted C1-C6 alkyloxy, optionally substituted C2-C6 alkenyloxy, optionally substituted C2-C6 alkynyloxy, optionally substituted C3-C6 cycloalkyloxy, optionally substituted C3-C6 cycloalkenyloxy, optionally substituted aryloxy, optionally substituted heteroaryloxy, optionally substituted C1-C6 alkylthio, optionally substituted C2-C6 alkenylthio, optionally substituted C2-C5 alkynylthio, optionally substituted C3-C5 cycloalkylthio, optionally substituted C3-C6 cycloalkenylthio, optionally substituted arylthio or optionally substituted heteroarylthio; R4 is independently a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, hydroxy, optionally substituted alkyloxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted cycloalkyloxy, optionally substituted cycloalkenyloxy, mercapto, optionally substituted alkylthio, optionally substituted alkenylthio, optionally substituted alkynylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted alkylsulfonyloxy, optionally substituted cycloalkylthio, optionally substituted cycloalkylsulfmyl, optionally substituted cycloalkylsulfonyl, optionally substituted cycloalkylsulfonyloxy, optionally substituted cycloalkenylthio, optionally substituted cycloalkenylsulfinyl, optionally substituted cycloalkenylsulfonyl, optionally substituted cycloalkenylsulfonylox}% optionally substituted amino, acyl, optionally substituted alkyloxycarbonyl, optionally substituted alkenyloxycarbonyl, optionally substituted alkynyloxycarbonyl, optionally substituted aryloxycarbonyl, optionally substituted carbamoyl, optionally substituted sulfamoyl, cyano, nitro, optional^ substituted aryl, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted arylsulfinyl, optionally substituted arylsulfonyl, optionally substituted arylsulfonyloxy, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heteroarylthio, optionally substituted heteroarylsulfinyl, optionally substituted heteroaiylsulfonyl, optionally substituted heteroarylsulfonyloxy or an optionally substituted non-aromatic heterocyclic group; R5 is independently a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl,. optionally substituted cycloalkyl, optionally substituted alkyloxy, oxo, optionally substituted aryl, optionally substituted heteroaryl or an optionally substituted non-aromatic heterocyclic group; M is carbonyl or sulfonyl; L3 is independently a single bond, optionally substituted alkylene optionally containing one or two heteroatom(s), optionally substituted alkenylene optionally containing one or two heteroatomfs), optionally substituted alkynylene optionally containing one or two heteroatom(s) or -N(R'^)-; R7 is hydrogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, acyl, optionally substituted alkyloxy, optionally substituted aryl, optionally substituted heteroaryl or an optionally substituted non-aromatic heterocyclic group, Y is a single bond or optionally substituted alkylene optionally containing one or two heteroatom(s); Z is CH, C(R4) or N; n is 0, 1 or 2; p is 1, 2, 3 or 4; and q is 0, 1, 2 or 3; provided that a) R1 is not carboxy when the ring D is a benzene ring, -L^- is -(O-alkylene)-, and the substituting position of L^ and Y is an ortho-position in the ring D, b) the group of the formula of position of L3 and Y is a para-position in the ring D; a pharmaceutically acceptable salt or solvate thereof, 36) a compound of 35) wherein R1 is carboxy and -L3- is -(O-optionally substituted alkylene)-; a pharmaceutically acceptable salt or solvate thereof, 37) a compound of 35) or 36) wherein the ring D is a benzene ring or a pyridine ring; a pharmaceutically acceptable salt or solvate thereof, 38) a compound of any of 35) to 37) wherein R3 is optionally substituted CI- C5 alkyloxy, or optionally substituted C1-C6 alkylthio; a pharmaceutically acceptable salt or solvate thereof, 39) a compound of any of 35) to 38) wherein M is sulfonyl; a pharmaceutically acceptable salt or solvate thereof, 40) a compound of any of 35) to 39) wherein Y is a single bond; a pharmaceutically acceptable salt or solvate thereof, 41) a compound of any of 35) to 40) wherein R2 is a halogen atom., optionally substituted alkyl, optionally substituted alkyloxy, optionally substituted amino, optionally substituted carbamoyl, optionally substituted aiyl, optionally substituted heteroaryl or an optionally substituted non-aromatic heterocyclic group, and p is 1 or 2; a pharmaceutically acceptable salt or solvate thereof, 42) a compound of any of 35) to 41) wherein R2 is a halogen atom, optionally substituted amino, optionally substituted carbamoyl, optionally substituted aryl, optionally substituted heteroaryl or an optionally substituted non-aromatic heterocyclic group, and p is 1 or 2; a pharmaceutically acceptable salt or solvate thereof, 43) a compound of any of 35) to 42) wherein R4 is a halogen atom, optionally substituted alkyl or optionally substituted alkyloxy, and q is 0 or 1, a pharmaceutically acceptable salt or solvate thereof, 44) a compound of any of 35) to 43) wherein the substituting position of Y and L3 is a meta-position in the ring D, a pharmaceutically acceptable salt or solvate thereof, 45) a pharmaceutical composition comprising a compound of any of 14) to 44), a pharmaceutically acceptable .salt or solvate thereof as an active ingredient. 46) a pharmaceutical composition of 45) which is a DP receptor antagonist, 47) a pharmaceutical composition of 45) which is a therapeutic agent for allergy, 48) a pharmaceutical composition of 45) which is a therapeutic agent for asthma, 49) a method for treating a disease related to DP receptor characterized by administration of the compound of any of 1) to 11) and 14) to 44), pharmaceutically acceptable salt or solvate thereof, 50) a method of 49) wherein the disease related to DP receptor is asthma, 51) use of the compound of any of 1) to 11) and 14) to 44), pharmaceutically acceptable salt or solvate thereof in the manufacturing of a therapeutic agent for treating a disease related to DP receptor, 52) use of the compound of 51), pharmaceutically acceptable salt or solvate thereof wherein the disease related to DP receptor is asthma, wherein the ring D is a benzene ring, a naphthalene ring, a 2-pyridone ring, a pyridine ring, a benzoxazolone ring, a benzoxadinone ring or a benzimidazole ring; R1 is hydroxyalkyl, carboxy, alkyloxycarbonyl, optionally substituted carbamoyl, cyano or a carboxy equivalent; R2 is independently a hydrogen atoms, a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycioalkyl, optionally substituted cycloalkenyl, hydroxy, optionally substituted alkyloxy, optionally substituted alkenyloxy, optional^ substituted alkynyloxy, optionally substituted cycloalkyloxy, optionally substituted cycle alkenyloxy, mercapto, optionally substituted alkylthio, optionally substituted alkenylthio, optionally substituted alkynylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted alkylsulfonyloxy, optionally substituted cycloalkylthio, optional^ substituted cycloalkylsulfinyl, optionally substituted cycloalkylsulfonyl, optionally substituted cycloalkylsulfonyloxy, optionally substituted cycioalkenylthio, optionally substituted cycloalkenylsuituny optionally substituted cycloalkenylsulfonyl, optionally substituted cycloalkenylsulfonyloxy, optionally substituted amino, acyl, optionally substituted alkyloxycarbonyi, optionally substituted alkenyloxycarbonyl, optionally substituted alkynyloxycarbonyl, optionally substituted aryloxycarbonyl, optionally substituted carbamoyl, optionally substituted sulfamoyl, cyano, nitro, optionally substituted aryl, optionally substituted arylox}^ optionally substituted arylthio, optionally substituted aryisulfinyl, optionally substituted arylsulfonyl, optionally substituted arylsulfonyloxy, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heteroarylthio, optionally substituted heteroarylsulfinyl, optionally substituted heteroarylsulfonyl, optionally substituted heteroarylsulfonyloxy or an optionally substituted non-aromatic heterocyclic group; L3 is independently a single bond, optionally substituted alkylene optionally containing one or two heteroatom(s), optionally substituted alkenylene optionally containing one or two heteroatom(s), optionally substituted alkynylene optionally containing one or two heteroatom(s) or -N(R'7)-; R7 is a hydrogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, acyl, optionally substituted alkyloxy, optionally substituted aryl, optionally substituted heteroaryl or an optionally substituted non-aromatic heterocyclic group; R8 is a halogen atom, trifluoromethanesulfonyloxy or piperazino; and p is 1, 2, 3 or 4; provided that the substituting position of the piperidino group and L3 each other is not an ortho-position in the ring D when the ring D is a benzene ring and -L^- is -(O-alkylene)-; a pharmaceutically acceptable salt or hydrate thereof, 54) a compound of 53) wherein the ring D is a benzene ring and Rs is a halogen atom; a pharmaceutically acceptable salt or solvate thereof, 55) a compound of 53) wherein the ring D is a benzene ring and Rs is piperazino; a pharmaceutically acceptable salt or solvate thereof, 56) a compound of any of 53) to 55) wherein R1 is carboxy or alkyloxycarbonyl and -L3- is -(0-methylene)-; a pharmaceutically acceptable salt or solvate thereof, 57) a compound of any of 53) to 55) wherein R2 is a halogen atom, optionally substituted amino, optionally substituted carbamoyl, optionally substituted aryl, optionally substituted heteroaryl or an optionally substituted non-aromatic heterocyclic group; a pharmaceutically acceptable salt or hydrate thereof, and 58) a compound of any of 53) to 57) wherein the substituting position of R^ and L3 each other is a meta-position in the ring D; a pharmaceutically acceptable salt or solvate thereof. wherein the ring Ab is an aromatic carbocyclic ring or an aromatic heterocyclic ring; the ring Bb is a 3- to 8-membered nitrogen-containing heterocyclic ring containing one or two nitrogen atom(s); the ring Cb is a benzene ring, a naphthalene ring, a 2-pyrdone ring or a pyridine ring; R1b is hydroxyalkyl, carboxy, alkyloxycarbonyl, optionally substituted carbamoyl or optionally substituted tetrazolyl; R2b is independently a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, hydroxy, optionally substituted alkyloxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted alkylthio, optionally substituted alkenylthio, optionally substituted alkynylthio, optionally substituted alkylsulfmyl, optionally substituted alkylsulfonyl, optionally substituted alkylsulfonyloxy, optionally substituted amino, acyl, optionally substituted alkyloxycarbonyl, optionally substituted alkenyloxycarbonyl, optionally substituted alkynyloxycarbonyl, optionally substituted carbamoyl, cyano, nitro, optionally substituted aiyl, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted arylsulfinyl, optionally substituted arylsulfonyl, optionally substituted arylsulfonyloxy, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heteroarylthio, optionally substituted heteroarylsulfinyl, optionally substituted heteroarylsulfonyl, optionally substituted heteroarylsulfonyloxy or an optionally substituted non-aromatic heterocyclic group; R3b is optionally substituted alkyloxy, optionally substituted alkylthio, optionally substituted cycloalkyloxy, optionally substituted cycloalkylthio, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted heteroaryloxy or optionally substituted heteroarylthio; R4b is independently a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted alkyloxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted alkylthio, optionally substituted alkenylthio, optionally substituted alkynylthio, optionally substituted alkylsulfmyl, optionally substituted alkylsulfonyl, optionally substituted alkylsulfonyloxy, optionally substituted amino, acyl, optionally substituted alkyloxycarbonyl, optionally substituted alkenyloxycarbonyl, optionally substituted alkynyloxycarbonyl, optionally substituted carbamioyl, cyano, nitro, optionally substituted aryl, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted arylsulfinyl, optionally substituted arylsulfonyl, optionally substituted arylsulfonyloxy, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heteroarylthio, optionally substituted heteroarylsulfinyl, optionally substituted heteroaiylsulfonyl, optionally substituted heteroarylsulfonyloxy or an optionally substituted non-aromatic heterocyclic group; R5b, is independently optionally substituted alkyl or optionally substituted aryl; Yb is a single bond, alkylene, alkenylene, alkynylene, -0-, -S-, -O-alkylene- or -S-alkylene-; Zb is a single bond, alkylene, alkenylene, alkynylene, -0-alkylene- or -S-alkylene-; kb is 0, 1, 2, 3 or 4; mb is 0, 1 or 2; nb is 0, 1 or 2; and pb is 0 or 1; provided that k is not 0 when the ring B is a 6-ineinbered nitrogen-containing heterocyclic ring containing one or two nitrogen atom(s) and the ring C is a benzene ring; a pharmaceutically acceptable salt or hydrate thereof, (2) a PGD2 receptor antagonist of (1) wherein the ring Cb is a benzene ring or a pyridine ring, and nb is 0 or 1, (4) a PGD2 receptor antagonist of any of (1) to (3) wherein the ring Ab is a benzene ring or a pyridine ring, (5) a PGD2 receptor antagonist of any of (1) to (4) wherein pb is 1, (6) a PGD2 receptor antagonist of any of (1) to (5) wherein Y^ is a single bond or -0-, (7) a PGD2 receptor antagonist of any of (1) to (5) wherein R1b is carboxy, (8) a PGD2 receptor antagonist of any of (1) to (7) which is a therapeutic agent for allergy, (9) a PGD2 receptor antagonist of any of (1) to (7) which is a therapeutic the ring Bb is a 3- to 8-membered nitrogen-containing heterocyclic ring containing one or two nitrogen atom(s); the ring Cb is a benzene ring, a naphthalene ring, a 2-pyridone ring or a pyridine ring; Ri^ is hydroxyalkyl, carboxy, alkyloxycarbonyl, optionall}^ substituted carbamoyl or optionally substituted tetrazolyl; R2b is independently a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, hydroxy, optionally substituted alkyloxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted alkylthio, optionally substituted alkenylthio, optionally substituted alkynylthio, optionally substituted alkylsulfmyl, optionally substituted alkylsulfonyl, optionally substituted alkylsulfonyloxy, optionally substituted amino, acyl, optionally substituted alkyloxycarbonyl, optionally substituted alkenyloxycarbonyl, optionally substituted alkynyloxycarbonyl, optionally substituted carbamoyl, cyano, nitro, optionally substituted aryl, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted arylsulfmyl, optionally substituted arylsulfonyl, optionally substituted arylsulfonyloxy, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heteroarylthio, optionally substituted heteroarylsulfinyl, optionally substituted heteroarylsulfonyl, optionally substituted heteroarylsulfonyloxy or an optionally substituted non-aromatic heterocyclic group; R3b is optionally substituted alkyloxy, optionally substituted alkylthio, optionally substituted cycloalkyloxy, optionally substituted cycloalkylthio, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted heteroaryloxy or optionally substituted heteroarylthio; R4b is independently a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted alkyloxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted alkylthio, optionally substituted alkenylthio, optionally substituted alkyllthio, optionally substituted alkylsulfmyl, optionally substituted alkylsulfonyl, optional!}^ substituted alkylsulfonyloxy, optionally substituted amino, acyl, optionally substituted alkyloxycarbonyl, optionally substituted alkenyloxycarbonyl, optionally substituted alkynyloxycarbonyl, optionally substituted carbamoyl, cyano, nitro, optionally substituted aryl, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted arylsulfinyl, optionally substituted arylsulfonyl, optionally substituted arylsulfonyloxy, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heteroarylthio, optionally substituted heteroarylsulfinyl, optionally substituted heteroarylsulfonyl, optionally substituted heteroarylsulfonylox}^ or an optionally substituted non-aromatic heterocyclic group; R5b is independently optionally substituted alkyl or optionally substituted aryl; Yb is a single bond, alkylene, alkenylene, alkynylene, -0-, -S-, -O-alkylene- or -S-alkylene-; Zb is is a single bond, alkylene, alkenylene, alkynylene, -O-alkylene- or -S-alkylene-; and n is 0 or 1; a pharmaceutically acceptable salt or hydrate thereof, (12) a compound of (10) or (11) wherein the ring C is a benzene ring or a Pyridine ring; a pharmaceutically acceptable salt or hydrate thereof, (13) a compound of any of (10) to (12) wherein R3b is optionally substituted alkyloxy or optionally substituted alkylthio; a pharmaceutically acceptable salt or hydrate thereof, (14) a compound of any of (10) to (13) wherein R1b is carboxy; a pharmaceutically acceptable salt or hydrate thereof, (15) a compound of the general formula (Ill-b): wherein the ring Cb is a benzene ring, a naphthalene ring, a 2-pyridone ring or a pyridine ring; R1b is hydroxyalkyl, carboxy, alkyloxycarbonyl, optionally substituted carbamoyl or optionally substituted tetrazolyl; R2b is independently a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, hydroxy, optionally substituted alkyloxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted alkylthio, optionally substituted alkenylthio, optionally substituted alkynylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted alkylsulfonyloxy, optionally substituted amino, acyl, optionally substituted alkyloxy carbonyl, optionally substituted alkenyloxycarbonyl, optionally substituted alkynyloxycarbonj^-l, optionally substituted carbamoyl, cyano, nitro, optionally substituted aryl, optionally substituted aryloxy, optionally substituted arylthio, optionalty substituted arylsulfmyl, optionally substituted arylsulfonyl, optionally substituted arylsulfonyloxy, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heteroarylthio, optionally substituted heteroarylsulfinyl, optionally substituted heteroaiylsulfonylj optionally substituted heteroarylsulfonyloxy or an optionally substituted non-aromatic heterocyclic group; R3b is optionally substituted alkyloxy, optionally substituted alkylthio, optionally substituted cycloalkyloxy, optionally substituted cycloalkylthio, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted heteroaryloxy or optionally substituted heteroarylthio, R4b is independently a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted alkyloxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted alkylthio, optionally substituted alkenylthio, optionally substituted alkynylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted alkylsulfonyloxy, optionally substituted amino, acyl, optionally substituted alkyloxycarbonyl, optionally substituted alkenyloxycarbonyl, optionally substituted alkynyloxycarbonyl, optionally substituted carbaxaoyi, cyano, nitro, optionally substituted aryl, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted aiylsulfinyl, optionally substituted arylsulfonyl, optionally substituted arylsulfonyloxy, optionally substituted heteroaiyl, optionally substituted heteroaryloxy, optionally substituted heteroarylthio, optionally substituted heteroarylsulfinyl, optionally substituted heteroarylsulfonyl, optionally substituted heteroarylsulfonyloxy or an optionally substituted non-aromatic heterocyclic group; R5b is independently optionally substituted alkyl and optionally substituted aryl; Xb is CH or N; Yb is a single bond, alkylene, alkenylene, alkynylene, -0-, -S-, -O-alkylene- or -S-alkylene-; Z^ is a single bond, alkylene, alkenylene, alkynylene, -0-alkylene- or -S-alkylene-; mb is 0, 1 or 2; nb is 0, 1 or 2; and qb is 1, 2, 3 or 4; a pharmaceutically acceptable salt or hydrate thereof, (16) a compound of 15) wherein the ring Cb is a benzene ring or a pyridine ring; a pharmaceutically acceptable salt or hydrate thereof, (17) a compound of (15) or (15) wherein R3b is optionally substituted alkyloxy(the substituent is a halogen atom, alkyloxy, aryl or heteroaryl), optionally substituted alkylthio(the substituent is a halogen atom, alkyloxy, aryl or heteroaryl), optionally substituted cycloalkyloxy(the substituent is a halogen atom, alkyl, aryl or heteroaryl), optionally substituted cycloalkylthio(the substituent is a halogen atom, alkyloxy, aryl or heteroaryl), optionally substituted aryloxy(the substituent is a halogen atom., alkyl or alkyloxy), optionally substituted arylthio(the substituent is a halogen atom., alkyl or alkyloxy), optionally substituted heteroaryloxy(the substituent is a halogen atom, alkyl or haloalkyl), or optionally substituted heteroarylthio(the substituent is a halogen atom, alkyl or haloalkyl); a pharmaceutically acceptable salt or hydrate thereof, (18) a compound of (15) or (16) wherein R3b is optionally substituted alkyloxy(the substituent is a halogen atom, alkyloxy, aryl or heteroaryl) or alkylthio(the substituent is a halogen atom, alkyloxy, aryl or heteroaryl); a pharmaceutically acceptable salt or hydrate thereof, (19) a compound of any of (15) to (18) wherein R2b is a halogen atom, cyano, nitro or optionally substituted heteroaryl; a pharmaceutically acceptable salt or hydrate thereof, (20) a compound of any of (15) to (19) wherein R2b is optionally substituted 5-membered heteroaryl; a pharmaceutically acceptable salt or hydrate thereof, (21) a compound of any of (15) to (20) wherein R1b is carboxy; a pharmaceutically acceptable salt or hydrate thereof, (22) a compound of the general formula (IV-b): Rib is hydroxyalkyl, carboxy, alkyloxycarbonyl, optionally substituted carbamoyl or optionally substituted tetrazolyl; R2b is independently a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, hydroxy, optionally substituted alkyloxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted alkylthio, optionally substituted alkenylthio, optionally substituted alkynylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted alkylsulfonyloxy, optionally substituted amino, acyl, optionally substituted alkyloxycarbonyl, optionally substituted alkenyloxycarbonyl, optionally substituted alkynyloxycarbonyl, optionally substituted carbamoyl, cyano, nitro, optionally substituted aryl, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted arylsulfmyl, optionally substituted arylsulfonyl, optionally substituted arylsulfonyloxy, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heteroarylthio, optionally substituted heteroaiylsulfinyl, optionally substituted heteroarylsulfonyl, optionally substituted heteroarylsulfonyloxy or an optionally substituted non-aromatic heterocyclic group; R3b is optionally substituted alkyloxy, optionally substituted alkylthio, optionally substituted cycloalkyloxy, optionally substituted cycloalkylthio, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted heteroaryloxy or optionally substituted heteroarylthio; R4b is independently a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted alkyloxy, optionally substituted alkenylox}^ optionally substituted alkynyloxy, optionally substituted alkylthio, optionally substituted alkenythio, optionally substituted alkynylthio, optionalh^ substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted alkylsulfonyloxy optionally substituted amino, acyl, optionally substituted alkyloxycarbonyl, optionally substituted alkenyloxycarbonyl, optionally substituted alkynyloxcarbonyl, optionally substituted carbamoyl, cyano, nitro, optionally substituted aiyl, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted arylsulfinyl, optionally substituted arylsulfonyl, optionally substituted arylsulfonyloxy, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heteroarylthio, optionally substituted heteroarylsulfinyl, optionally substituted heteroarylsulfonyl, optionally substituted heteroarylsulfonyloxy, or an optionally substituted non-aromatic heterocyclic group; R5b is independently optionally substituted alkyl or optionally substituted aryl; Xb is CH or N; Yb is a single bond, alkylene, alkenylene, alkynylene, -0-, -S-, -O-alkylene- or -S-alkylene-; Zb is a single bond, alkylene, alkenylene, alkynylene, -0-alkylene- or -S-alkylene-; mb is 0, 1 or 2 nb is 0, 1 or 2; and sb is 1, 2, 3 or 4; a pharmaceutically acceptable salt or hydrate thereof, (23) a compound of 22) wherein the ring Cb is a benzene ring or a pyridine ring; a pharmaceutically acceptable salt or hydrate thereof, (24) a compound of (22) or (23) wherein R3b is optionally substituted alkyloxy(the substituent is a halogen atom, alkyloxy, aryl or heteroaryl), optionally substituted alkylthio(the substituent is a halogen atom, alkyloxy, aryl or heteroaiyl), optionally substituted cycloalkyloxy(the substituent is a halogen atom, alkyl, aryl or heteroaiyl), optionally substituted cycloalkylthio(the substituent is a halogen atom, alkyloxy, aryl or heteroaryl), optionally substituted aryloxy(the substituent is a halogen atom, alkyl or alkyloxy), optionally substituted arylthio(the substituent is a halogen atom, alkyl or alkyloxy), optionally substituted heteroaryloxy(the substituent is a halogen atom, alkyl or haloalkyl), or optionally substituted heteroarylthio(the substituent is a halogen atom, alkyl or haloalkyl); a pharmaceutically acceptable salt or hydrate thereof, (25) a compound of (22) or (23) wherein R3b is optionally substituted alkyloxy(the substituent is a halogen atom, alkyloxy, aryl or heteroaryl), optionally substituted alkylthio(the substituent is a halogen atom, alkyloxy, aryl or heteroaryl); substituted heteroaiylsulfonyloxy or an optionally substituted non-aromatic heterocyclic group; R3b is optionally substituted alkyloxy, optionally substituted alkylthio, optionally substituted cycloalkyloxy, optionally substituted cycloalkylthio, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted heteroaryloxy or optionally substituted heteroarylthio; R4b is independently a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted alkyloxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted alkylthio, optionally substituted alkenylthio, optionally substituted alkynylthio, optionally substituted alkylsulfinyl, optionedly substituted alkylsulfonyl, optionally substituted alkylsulfonyloxy, optionally substituted amino, acyl, optionally substituted alkyloxycarbonyl, optionally substituted alkenyloxycarbonyl, optionally substituted alkynyloxycarbonyl, optionally substituted carbamoyl, cyano, nitro, optionally substituted aryl, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted arylsulfmyl, optionally substituted arylsulfonyl, optionally substituted arylsulfonyloxy, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heteroarylthio, optionally substituted heteroarylsulfinyl, optionally substituted heteroarylsulfonyl, optionally substituted heteroaiylsulfonyloxy or an optionally substituted non-aromatic heterocyclic group; Xb is CH or N; Wb is a single bond, alkylene or -0-; Zb is a single bond, alkylene, alkenylene, alkynylene, -O-alkylene- or -S-alkylene-; mb is 0, 1 or 2; and sb is 1, 2, 3 or 4; a pharmaceutically acceptable salt or hydrate thereof, (28) a compound of (27) wherein the ring Cb is a benzene ring or a pyridine ring; a pharm.aceutically acceptable salt or hydrate thereof, (29) a compound of (27) or (28) wherein R3b is optionally substituted alkyloxy(the substituent is a halogen atom, alkyloxy, aryl or heteroaryl), optionally substituted alkylthio(the substituent is a halogen atora, alkyloxy, aryl or heteroaryl), optionally substituted cycloalkyloxy(the substituent is a halogen atom, alkyl, aryl or heteroaryl), optionally substituted cycloalkylthio(the substituent is a halogen atom, alkyloxy, aryl or heteroaryl), optionally substituted aryloxy(the substituent is a halogen atom, alkyl or alkyloxy), optionally substituted arylthio(the substituent is a halogen atom, alkyl or alkyloxy), optionally substituted heteroaryloxy(the substituent is a halogen atom, alkyl or haloalkyl), or optionally substituted heteroarylthio(the substituent is a halogen atom, alkyl or haloalkyl); a pharmaceutically acceptable salt or hydrate thereof, (30) a compound of (27) or (28) wherein R3b is optionally substituted alkyloxy(the substituent is a halogen atom, alkyloxy, aryl or heteroaryl), optionally substituted alkylthio(the substituent is a halogen atom, alkyloxy, aryl or heteroaiyl); a pharmaceutically acceptable salt or hydrate thereof, (31) a compound of any of (27) to (30) wherein R1b is carboxy; a pharmaceutically acceptable salt or hydrate thereof, (32) a pharmaceutical composition comprising a compound of any of (10) to (31), a phannaceutically acceptable salt or hydrate thereof as an active ingredient, (33) a pharmaceutical composition of (32) which is a DP receptor antagonist, (34) a pharmaceutical composition of (32) which is a therapeutic agent for allergy, (35) a pharmaceutical composition of (32) which is a therapeutic agent for asthmia, (36) a method for treating a disease related to DP receptor characterized by administration of the compound of any of (1) to (7) and (10) to (31), pharmaceutically acceptable salt or hydrate thereof, (37) a method of (36) wherein the disease related to DP receptor is asthma, (38) use of the compound of any of (1) to (7) and (10) to (31), pharmaceutically acceptable salt or hydrate thereof in the manufacturing of a therapeutic agent for treating a disease related to DP receptor, and (39) use of the compound of (38), pharmaceutically acceptable salt or hydrate thereof wherein the disease related to DP receptor is asthma. The present invention also includes the following inventions: [1] a PDG2 antagonist comprising a compound of the general formula (I-a): the ring B-a is a 4- to 8-membered nitrogen-containing heterocyclic ring containing one or two nitrogen atoin(s); the ring C-a is a benzene ring, a naphthalene ring or a pyridine ring; R1a is hydroxyalkyl, carboxy, alkyloxycarbonyl, optionally substituted carbamoyl or optionally substituted tetrazolyl; R2a is independently a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted alkyloxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted alkylthio, optionally substituted alkenylthio, optionally substituted alkynylthio, optionally substituted alkylsulfmyl, optionally substituted alkylsulfonyl, optionally substituted alkylsulfonyloxy, optionally substituted amino, acyl, optionally substituted alkyloxycarbonyl, optionally substituted alkenyloxycarbonyl, optionally substituted alkynyloxycarbonyl, optionally substituted carbamoyl, cyano, nitro, optionally substituted aryl, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted arylsulfmyl, optionally substituted arylsulfonyl, optionally substituted arylsulfonyloxy, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heteroarylthio, optionally substituted heteroaiylsulfinyl, optionally substituted heteroarylsulfonyl, optionally substituted heteroarylsulfonyloxy or an optionally substituted non-aromatic heterocyclic group; R3a is optionally substituted alkyloxy, optionally substituted alkylthio, optionally substituted cycloalkydoxy, optionally substituted cycloalkylthio, optionally substituted aiyloxy, optionally substituted arylthio, optionally substituted heteroaryloxy, or optionally substituted heteroarylthio; R4a is independently a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted alkyloxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted alkylthio, optionally substituted alkenylthio, optionally substituted alkynylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted alkylsulfonyloxy, optionally substituted amino, acyl, optionally substituted alkyloxycarbonyl, optionally substituted alkenyloxycarbonyl, optionally substituted alkynyloxycarbonyl, optionally substituted carbamoyl, cyano, nitro, optionally substituted aryl, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted arylsulfmyl, optionally substituted arylsulfonyl, optionally substituted arylsulfonyloxy, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heteroarylthio, optionally substituted heteroarylsulfmyl, optionally substituted heteroarylsulfonyl, optionally substituted heteroarylsulfonyloxy or an optionally substituted non-aromatic heterocyclic group; R5a is independently optionally substituted alkyl or optionally substituted aryl; Ya is a single bond, alkcylene, alkenylene, alkynylene, -0-, -S-, -O-alkylene- or -S-alkylene-; Z^ is a single bond, alkylene, alkenylene, alkynylene, -O-alkylene- or -S-alkylene-; kais 0, 1, 2, 3 or 4; ma is 0, 1 or 2; na is 0, 1 or 2; and pa is 0 or 1; provided that ka is not 0 when the ring B-a is a 6-membered nitrogen-containing heterocyclic ring containing one or two nitrogen atom(s) and the ring C-a is a benzene ring; a pharmaceutically acceptable salt or hydrate thereof as an active ingredient, [2] a PGD2 antagonist of [1] wherein the ring C-a is a benzene ring or a pyridine ring, [3] a PGD2 antagonist of [1] or [2] wherein the ring B-a is a ring of the formula of wherein the ring B-a is a 4- to 8-membered nitrogen-containing heterocyclic ring containing one or two nitrogen atoin(s); the ring C-a is a benzene ring, a naphthalene ring or a pyridine ring; R1a is hydroxyalkyl, carboxy, alkyloxycarbonyl, optionally substituted carbamoyl or optionally substituted tetrazolyl; R2a is independently a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkjd, optionally substituted alkyloxy, optionally substituted alkenylojcy, optionally substituted alkynyloxy, optionally substituted alkylthio, optionalty substituted alkenylthio, optionally substituted alkynylthio, optionally substituted alkydsulfmyl, optionally substituted alkylsulfonyl, optionally substituted alkylsulfonyloxy, optionally substituted amino, acyl, optionally substituted alkyloxycarbonyl, optionally substituted alkenyloxycarbonyl, optionally substituted alkynyloxycarbonyl, optionally substituted carbamoyl, cyano, nitro, optionally substituted aryl, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted arylsulfinyl, optionally substituted arylsulfonyl, optionally substituted arylsulfonyloxy, optionally substituted heteroaryl, optionally substituted heteroaryloxyj optionally substituted heteroarylthio, optionally substituted heteroarylsulfinyl, optionally substituted heteroaiylsulfonyl, optionally substituted heteroarylsulfonylox}^ or an optionally substituted non-aromatic heterocyclic group; R3a is optionally substituted alkyloxy, optionally substituted alkylthio, optionally substituted cycloalkyloxy, optionally substituted cycloalkylthio, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted heteroaiyloxy or optionally substituted heteroarylthio; R4a is independently a halogen atom., optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted alkyloxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted alkylthio, optionally substituted alkenylthio, optionally substituted alkynylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted alkylsulfonyloxy, optionally substituted amino, acyl, optionally substituted alkyloxycarbonyl, optionally substituted alkenyloxycarbonyl, optionally substituted alkynyloxycarbonyl, optionally substituted carbamoyl, cyano, nitro, optionally substituted aryl, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted arylsulfinyl, optionally substituted arylsulfonyl, optionally substituted arylsulfonyloxy, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heteroarylthio, optionally substituted heteroarylsulfinyl, optionall}^ substituted heteroarylsulfonyl, optionally substituted heteroarjdsulfonyloxy or an optionally substituted non-aromatic heterocyclic group; R5a is independently optionally substituted alkyl or optionally substituted aryl; Ya is a single bond, alkylene, alkenylene, alkynylene, -0-, -S-, -O-alkylene- or -S-alkylene-; Za is a single bond, alkylene, alkenylene, alkynylene, -O-alkjdene- or -S-alkylene-; • R3a is optionally substituted alkyloxy, optionally substituted alkylthio, optionally substituted cycloalkyloxy, optionally substituted cycloalkylthio, optionaly substituted aryloxy, optionally substituted arylthio, optionally substituted heteroaryloxy or optionally substituted heteroarylthio; R4a is independently a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optional^ substituted alkynyl, optional^ substituted cycloalkyl, optionally substituted alkyloxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted alkylthio, optionally substituted alkenylthio, optionally substituted alkynylthio, optionally substitaited alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted alkylsulfonyloxy, optionally substituted amino, acyl, optionally substituted alkyloxycarbonyl, optionally substituted alkenyloxycarbonyl, optionally substituted alkynyloxycarbonyl, optionally substituted carbamoyl, cyano, nitro, optionally substituted atyl, optionally substituted aiyloxy, optionally substituted arylthio, optionally substituted arylsulfmyl, optionally substituted arylsulfonyl, optionally substituted arylsulfonyloxy, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heteroarylthio, optionally substituted heteroarylsulfinyl, optionally substituted heteroarylsulfonyl, optionally substituted heteroarylsulfonyloxy or an optionally substituted non-aromatic heterocyclic group; R5a is independently optionally substituted alkyl or optionally substituted aryl optionally substituted alkenyl, optionally substituted alkynyl, optionally -substituted cycloalkyl, optionally substituted alkylox}^ optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted alkjdthio, optionally substituted alkenylthio, optionally substituted alkynylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted alkylsulfonyloxy, optionally substituted amino, acyl, optionally substituted alkyloxycarbonyl, optionally substituted alkenyloxycarbon5d, optional^ substituted alkynyloxycarbonyl, optionally substituted carbamoyl, cyano, nitro, optionally substituted aryl, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted arylsulfinyl, optionally substituted aiylsulfonyl, optionally substituted arylsulfonyloxy, optionally substituted heteroaryl, optionally substituted heteroaiyloxy, optionally substituted heteroarylthio, optionally substituted heteroarylsulfinyl, optionally substituted heteroarylsulfonyl, optionally substituted heteroarylsulfonyloxy or an optionally substituted non-aromatic heterocyclic group; R5a is independentiy optionally substituted alkyl or optionally substituted aryl; Ya is a single bond, alkylene, alkenylene, alkynylene, -0-, -S-, -O-alkylene- or -S-alkylene-; Za^ is a single bond, alkylene, alkenylene, alkynylene, -O-alkylene- or -S-alkylene-; ma is 0, 1 or 2; na is 0, 1 or 2; sa is 1, 2, 3 or 4 R3a is optionally substituted alkyloxjs optionally substituted alkylthio, optionally substituted cycloalkyloxy, optionally substituted cycloalkj'-lthio, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted heteroaryloxy or optionally substituted heteroarylthio; R'^a is independentiy a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted alkyloxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted alkylthio, optional^ substituted alkenylthio, optionally substituted alkjnnylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted alkylsulfonyloxy, optionally substituted amino, acyl, optionally substituted alkyloxycarbonyl, optionally substituted alkenyloxycarbonyl, optionally substituted alkynyloxycarbonyl, optionally substituted carbamoyl, cyano, nitro, optionally substituted aryl, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted arylsulfinyl, optionally substituted arylsulfonyl, optionally substituted arylsulfonyloxy, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heteroarylthio, optionally substituted heteroarylsulfinyl, optionally substituted heteroarylsulfonyl, optionally a pharmaceutically acceptable salt or hydrate thereof, [27] a pharmaceutical composition comprising a compound of any of [10] to [26] a pharmaceutically acceptable salt or hydrate thereof as an active ingredient, In the present specification, a term of "hetero atom" means an oxygen atom, a sulfur atom and a nitrogen atom.. In the present specification, a term of "alkyF includes a monovalent straight or branched hydrocarbon group having one to eight carbon atom(s). For example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert- butyl, n-pentyl, isopentyl, neo-pentyl, n-hexyl, isohexyl, n-heptyl, n-octyl and In the present specification, a term of "^alkyloxy^ includes a group wherein an oxygen atom is substituted with one "alkyl" above and for example, methyloxy, ethyloxy, n-propyloxy, isopropyloxy, n-butyloxy, isobutyloxy, sec-butyl oxy, tert-butyloxy, n-pentyloxy, isopentyloxy, 2-pentyloxy, 3-pentyloxy, n-hexyloxy, isohexyloxy, 2-hexyloxy, 3-hexyIoxy, n-heptyloxy, n-octyloxy, and the like are exemplified. C1-C6 alkyloxy is preferred. Moreover, C1-C4 alkyloxy is further preferred. When a num.ber of carbon is specified, it mieans "alkyloxy" having the carbon number within the range. In the present specification, a term of "alkenyloxy" includes a group wherein an oxygen atom is substituted with one "alkenyl" above and for example, vinyloxy, allyloxy, 1-propenyloxy, 2-butenyloxy, 2-pentenylox5% 2-hexenyloxy, 2-heptenyloxy, 2-octenyIoxy and the like are exemplified. C2-C6 alkenyloxy is preferred. Moreover, C2-C4 alkenyloxy is further preferred. In the present specification, a term of "cycloalkenyloxy" includes a group wherein an oxygen atom is substituted with one "cycloalkenyl" above and for example, cyclopropenyloxy, cyclobutenyloxy, cyclopentenyloxy, cyclohexenyloxy, cycloheptenyloxy and cyclooctenyloxy are exemplified. C3-C6 cycloalkenyloxy is preferred. When a number of carbon is specified, it means "cycloalkenylox}^ having the carbon num.ber within the range. In the present specification, a term of "alkylthio" includes a group wherein a sulfur atom is substituted with one "alkyl" above, and for example, methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, isobutylthio, sec-butylthio, tert-butylthio, n-pentylthio, isopentylthio, 2-pentylthio, 3-pentylthio, n- In the present specification, a term of "alkynylthio^' includes a group wherein a sulfur atom is substituted with one "alkynyl" above and for example, ethynylthio, 1-propynylthio, 2-propynylthio, 2-butynylthio, 2-pentynylthio, 2-hexynylthio, 2-hept5niylthio, 2-octynylthio and the like are exemplified. C2-C6 alkynylthio is preferred. Moreover, C2-C4 alkynylthio is further preferred. When a number of carbon is specified, it means "alkynjdthio" having the carbon number within the range. In the present specification, a term of "alkylsulfinyl" includes a group wherein sulfinyl is substituted with one "alkyl" above and for example, methylsulfinyl, ethylsulfinyl, n-propylsulfinyl, isopropylsulfinyl, n-butylsulfinyl, isobutylsulfinyl, sec-butylsulfinyl, tert-butylsulfinyl, n-pentylsulfinyl, isopentylsulfinyl, 2-pentylsulfinyl, 3-pentylsulfinyl, n-hexylsulfinyl, isohexylsulfinyl, 2-hexylsulfinyl, 3-hexylsulfinyl, n-heptylsulfinyl, n-octylsulfinyl and the like are exemplified. C1-C6 alkylsulfinyl is preferred. Moreover, Cl-C4 alkylsulfinyl is further preferred. In the present specification, a term of "alkylsulfonyl" includes a group wherein sulfonyl is substituted with one "alkyF above and for example, methylsulfonyl, ethylsulfonyl, n-propylsulfonyl, isopropylsulfonyl, n-butylsulfonyl, isobutylsulfonyl, sec-butylsulfonyl, tert-butylsulfonyl, n-pentylsulfonyl, isopentylsulfonyl, 2-pentylsulfonyl, 3-pentylsulfonyl, n-hexylsulfonyl, isohexylsulfonyl, 2-hexylsulfonyl, 3-hexylsulfonyl, n-heptylsulfonyl, n-octylsulfonyl and the like are exemplified. C1-C6 alkylsulfonyl is preferred. Moreover, C1-C4 alkylsulfonyl is further preferred. In the present specification, a term of "alkylsulfonyloxy" includes a group wherein an oxygen atom is substituted with one "alkylsulfonyl" above and for example, methylsulfonyloxy, ethylsulfonyloxy, n-propylsulfonyloxy, isopropylsulfonyloxy, n-butylsulfonyloxy, isobutylsulfonyloxy, sec-butylsulfonyloxy, tert-butylsulfonyloxy, n-pentylsulfonyloxy, isopentylsulfonyloxy, 2-pentylsulfonylox5^ 3-pentylsulfonyloxy, n-hexylsulfonyloxy, isohexylsulfonyloxy 2-hexylsulfonyloxy, 3-hexylsulfonylox}% n-heptylsulfonyloxy, n-oct}4sulfonyloxy and the like are exemplified. C1-C6 alkylsulfonyl is preferred. Moreover, C1-C4 alkylsulfonyl is further preferred. In the present specification, a term of "cycloalkylthio" includes a group wherein a sulfur atom is substituted with one "cycloalkyl" above and for example, cyclopropylthio, cyclobutylthio, cyclopentylthio, cyclohexylthio, cycloheptylthio, cyclooctyltJiio and the like are exemplified. C3-C6 cycloalkylthio is preferred. When a number of carbon is specified, it means "cycloalkylthio" having the carbon number within the range. In the present specification, a term of "cycloalkylsulfinyl" includes a group in which sulfinyl is substituted with one "cycloalkyl" above. For examiple, cyclopropylsulfinyl, cyclobutylsulfinyl, cyclopentylsulfinyl, cyclohexylsulfinyl, cycloheptylsulfinyl, and cyclooctylsulfinyl are exemplified. Preferably C3-C6 cycloalkylsulfinyl is exemplified. In the present specification, a term of "cycloalkylsulfonyl" includes a group in which sulfonyl is substituted with one "cycloalkyl" above. For example, cyclopropylsulfonyl, cyclobutylsulfonyl, cyclopentylsulfonyl, cyclohexylsulfonyl, cycloheptylsulfonyl, and cyclooctylsulfonyl are exemplified. Preferably C3-C6 cycloalkylsulfonyl is exemplified. In the present specification, a term of "cycloalkylsulfonyloxy" includes a group in which an oxygen atom is substituted with one "cycloalkylsulfonyl" above. For example, cyclopropylsulfonyloxy, cyclobutylsulfonyloxy, cyclopentylsulfonyloxy, cyclohexylsulfonyloxy, cycloheptylsulfonyloxy, and cyclooctylsulfonyloxy are exem.plified. Preferably C3-C6 cycloalkylsulfonyloxy is exemplified. In the present specification, a term of "cycloalkenylthio" includes a group in which a sulfur atom is substituted with one "cycloalkenyl" above. For example, cyclopropenylthio, cyclobutenylthio, cyclopentenylthio, cyclohexenjdthio, cycloheptenylthio, and cyclooctenylthio are exemplified. Preferably C3-C6 cycloalkenylthio is exemplified. When a number of carbon is specified, it means "cycloalkenylthio" having the carbon number within the range. In the present specification, a term of "cycloalkenylsulfinyl" includes a group in which sulfinyl is substituted with one "cycloalkenyl" above. For example, cyclopropenylsulfinyl, cyclobutenylsulfinyl, cyclopentenylsulfinyl, cyclohexenylsulfinyl, cycloheptenylsulfinyl, and cyclooctenylsulfinyl are exemplified. Preferably C3-C6 cycloalkenylsulfinyl is exemplified. In the present specification, a term of "cycloalkenylsulfonyl" includes a group in which sulfonyl is In the present specification, a term of "alkyloxycarbonyl" includes a group in which carbonyl is substituted with one "alkyloxy" above. For example, methyloxycarbonyl, ethyloxycarbonyl, n-propyloxycarbonyl, isopropyloxycarbonyl, n-butyloxycarbonyl, tert-butyloxycarbonyl and n-pentyloxycarbonyl are exemplified. Preferably C1-C4 alkyloxycarbonyl is exemplified. Moreover, C1-C2 alkyloxycarbonyl is further preferable. In the present specification, a term of "alkenyloxycarbonyl" includes a group in which carbonyl is substituted with one "alkenyloxy" above. For example, vinyloxycarbonyl, aUyloxycarbonyl, 1-propenyloxycarbonyl, 2-butenyloxycarbonyl and 2-pentenyloxyarbonyl are exemplified. Preferably C2-C4 alkyloxycarbonyl is exemplified. In the present specification, a term of "alkynyloxycarbonyl" includes a group in which carbonyl is substituted with one "alkynyloxy" above. For example, ethynyloxycarbonyl, 1-propynyloxycarbonyl, 2-propynyloxycarbonyl, 2-butynyloxyarbonyl and 2-pent3niyloxycarbonyl are exemplified. Preferably C2-C4 alkynyloxycarbonyl is exemplified. In the present specification, a term of "acyl" includes alkylcarbonyl wherein the part of alkyl is "alkyl" before, alkenylcarbonyl wherein the part of alkenyl is "alkenyl" before, alkynylcarbonyl wherein the part of alkynyl is "alkynyl" before, cycloalkylcarbonyl wherein the part of cycloalkyl is "cycloalkyl" before, In the present specification, a term of "optionally substituted carbamoyl" includes an aminocarbonyl group wherein the part of optionally substituted amino is "optionally substituted amino" before and methylene, 1-metiiylmethylene, 1,1-dimethylinethylene, ethylene, 1-methylethylene, 1-ethylethylene, 1,1-dimethylethylene, 1,2-dimethylethylene, 1,1-diethylethylene, 1,2-diethylethylene, l-ethyl-2-methylethylene, trimethylene, 1 -methyltrimethylene, 2-methyltrimethylene, 1,1-dimethyltrimethyiene, 1,2-dimethyltrimethylene, 2,2-dimethyltrimethylene, 1-ethyltrimethylene, 2-ethyltrimethyiene, 1,1-diethyltrimethylene, 1,2-diethyltrimethylene, 2,2-diethyltrimethylene, 2-ethyl-2-methyltrimethylene, tetramethylene, l-methyltetramethylene, 2-methyltetramethylene, 1,1-dimethyltetramethylene, 1,2-dimethyltetramethylene, 2,2-dimethyltetramethylene, 2,2-di-n-propyltrimethylene etc. are exemplified. In the present specification, a term of "heteroaryl" in R2, R2a and R2b includes a 5- to 6-membered aromatic ring containing one or more of heteroatom(s) selected independently from oxygen, sulfur and nitrogen atoms and it may be fused with "cycloalkyl" before, "aryl" before, "non-aromatic heterocyclic group" or other heteroaryl at any possible position. The heteroaryl group may be substituted at any position whenever it is a monocyclic ring or a fused ring. For example, pyrrolyl(e.g., 1-pyrrolyl, 2-pyrolyl, 3-pyrrolyl), furyl(e.g., 2-furyl, 3-furyl), thienyl(e.g., 2-thienyl, 3-thienyl), imida2olyl(e.g., 2-imidazolyl, 4-imidazolyl), pyrazolyl(e.g., 1-pyrazolyl, S-pyrazolyl), isothiazolyl (e.g., 3-isothiazolyl), isoxazolyl(e.g., 3-isoxazolyl), oxazolyl(e.g., 2-oxazolyl), thiazolyl(e.g., 2-thiazolyl), pyridyl(e.g., 2-pyridyl, 3-pyridyl, 4-pyridyl), pyrazinyl(e.g., 2-pyTazinyl), pyrimidinyl(e.g., 2-pyrimidinyl, 4-pyrimidinyl), P5n:ida2;inyl(e.g., 3-pyridazinyl), tetrazolylfe.g., IH-tetrazolyl), oxadiazolyl(e.g., 1,3,4-oxadiazolyl), thiadiazolyl(e.g., 1,3,4-thiadiazolyl), indolidinyl(e.g., 2-indolidinyl, 6-indolidinyl), isoindolynyl(e.g., 2-isoindolynyl), indolyl(e.g., 1-indolyl, 2-indolyl, 3-indolyl), indazolyl(e.g., 3- indazolyl), purinyl(e.g., 8-purinyl), quinolidinyl(e.g., 2-quinolidinyl), isoquinolylfe.g., 3-isoquinolyl), quinolyl(e.g., 2-quinolyl, 5- before, "non-aromatic heterocyclic group" or other heteroaryl at any possible position. The heteroaiyl group may be substituted at any position whenever it is a monocyclic ring or a fused ring. For example, furyl(e.g., 2-furyl, 3-furyl), thienyl(e.g., 2-thienyl, 3-thienyl), imidazolyl(e.g., 2-imidazolyl, 4-imidazolyl), pyrazolyl(e.g., l-pyrazolyl, 3-pyrazolyl), isothiazolyl (e.g., 3-isothiazolyl), isoxazolyl(e.g., 3-isoxazolyl), oxazolyl(e.g., 2-oxazolyl), thiazolylfe.g., 2-thiazolyl), pyridyl(e.g., 2-pyridyl, 3-pyridyl, 4-pyridyl), pyrazinyl(e.g., 2-pyrazinyl), pyTimidinyl(e.g., 2-pyrimidinyl, 4-pyrimidinyl), pyrridazinyl(e.g., 3-p3aidazinyl), oxadiazolyl(e.g., 1,3,4-oxadiazolyl), thiadiazolyl(e.g., l,3,4-thiadia2olyl), benzoimidazolyl(e.g., 2-benzoimidazolyl), benzoisoxazolyl(e.g., 3-benzoisoxazolyl), benzooxazolyl(e.g., 2-benzooxazolyl), berLzofuryl(e.g., 3-benzofuryl), benzothienyl(e.g., 2-benzothienyl) etc. are exemplified. In the present specification, "2-pyridone" m.eans pyridine-2-one. In the present specification, a term of "aryloxy" includes a group in which an oxygen atom is substituted with one "aryl" before and for example, phenyloxy and naphthyloxy etc. are exemplified. In the present specification, a term of "arylthio" includes a group in which a sulfur atom is substituted with one "aryl" before and for example, phenylthio and naphthylthio etc. are exemplified. In the present specification, a term of "arylsulfinyl" includes a group in which sulfinyl is substituted with one "aryl" before and for example, phenylsulfinyl and naphthylsulfinyl etc. are exemplified. In the present specification, a term of "arylsulfonyl" includes a group in which sulfonyl is substituted with one "aryl" before and for example, phenylsulfonyl and naphthylsulfoinyl etc. are exemplified. pyrazinyioxy pyrimidinyloxy, pyridazinyloxy, tetrazolyloxy, oxadiazolyloxy, thiadiazolyloxy, indolidinyloxy, isoindolynyloxy, indolyloxy, indazolyloxy, purinyloxy, quinolidinyloxy, isoquinolyloxy, quinolyloxy, phtharazinyloxy, naphthylidinyloxy, quinolanyloxy, quinazolinyloxy, cinnolinyloxy, pteridinyloxy, carbazolyloxy, phenanthridinyloxy, acridinyloxy, dibenzofuranyloxy, benzoimidazolyloxy, benzoisoxazolyloxy, benzooxazolyloxy, benzooxadiazolyloxy, benzoisothiazolyloxy, benzothiazolyloxy, benzofuryloxy, benzothienyioxy, dibenzothienyloxy and benzodioxolyloxy are exemplified. Preferably fuiyloxy, thienyloxy, imidazolyloxy, pyrzolyloxy, isothiazolyloxy, isoxazolyloxy, oxazolyloxy, thiazolyloxy, pyridyloxy, pyrazinyloxy, pyrimidinyloxy and pyridazinyloxy are exemplified In the present specification, a term of "heteroarylthio" includes a group in which a sulfur atom is substituted with one "heteroaryl" before. For example, pyrrolylthio, furylthio, thienylthio, imidazolylthio, pyrazolylthio, isothiazolylthio, isoxazolylthio, oxazolylthio, thiazolylthio, pyridylthio, pyrazinylthio, pyrimidinylthio, pyridazinylthio, tetrazolylthio, oxadiazolylthio, thiadiazolylthio, quinazolinylsulfinyl, cinnolinylsulfmyl, pteridinylsulfinyl, carbazolylsulfmyl, phenanthridinylsulfmyl, acridinylsulfmyl, dibenzofuranylsulfinyl, benzoimidazolylsulfinyl, benzoisoxazotylsulfinyl, benzooxazolylsulfinyl, benzooxadiazolylsulfinyl, benzoisothiazolylsulfinyl, benzothiazolylsulfmyl, benzofurylsulfinyl, benzothienylsulfmyl, dibenzothienylsulfinyl and benzodioxolylsulfmyl etc. are exemplified. Preferably furylsulfinyl, thienylsulfmyl, imidazolylsulfinyl, pyrazolylsulfinyl, isothiazolylsulfinyl, isoxazolylsulfinyl, oxazolylsulfinyl, thiazolylsulfinyl, pyridylsulfinyl, pyrazinylsulfmyl, pyrimidinylsulfinyl and pyridazinylsulfinyl etc. are exemplified. In the present specification, a term of "heteroarylsulfonyl" includes a group in which sulfonyl is substituted with one "heteroaryl" before. For example, pyrrolylsulfonyl, furylsulfonyl, thienylsulfonyl, imidazolylsulfonyl, pyrazolylsulfonyl, isothiazolylsulfonyl, isoxazolylsulfonyl, oxazolylsulfonyl, thiazolylsulfonyl, pyridylsulfonyl, pyrazinylsulfonyl, pyrimidinylsulfonyl, pyridazinylsulfonyl, tetrazolylsulfonyl, oxadiazolylsulfonyl, thiadiazolylsulfonyl, indolizinylsulfonyl, isoindolylsulfonyl, indolylsulfonyl, indazolylsulfonyl, purinylsulfonyl, quinolidinylsulfonyl, isoquinolylsulfonyl, quinolylsulfonyl, phtharazinylsulfonyl, naphthilidinylsulfonyl, quinolanyl sulfonyl, quinazolinylsulfonyl, cinnolinylsulfonyl, pteridinylsulfonyl, carbazolylsulfonyl, phenanthridinylsulfonyl, acridinylsulfonyl, dibenzofuranylsulfonyl, benzoimidazolylsulfonyl, benzoisoxazolylsulfonyl, benzooxazoiylsulfonyl, benzooxadiazolylsulfonyl, benzoisothiazolylsulfonyl, benzothiazolylsulfonyl, benzofurylsulfonyl, benzothienylsulfonyl, dibenzothienylsulfonyl and benzodioxolylsulfonyl are exemplified. Preferably furylsulfonyl, thienylsulfonyl, imidazolylsulfonyl, pyrazolylsulfonyl, isothiazolylsulfonyl, isoxazolylsulfonyl, oxazolylsulfonyl, thiazolylsulfonyl, pyridylsulfonyl, pyrazinylsulfonyl, In t±ie present specification, a term of "azaindole" includes 4-a2aindole, 5-azaindole, 6-azaindole, 7-azaindole, 4,5-dia2aindole-, 4,6-diazaindole, 4,7-diazaindole, 5,6-diazaindole, 5,7-diazaindole, 6,7-diazaindole, 4,5,6-triazaindole, 4,5,7-triazaindole and 5,6,7-triazaindole. In the present specification, a term of "C1-C6 alkylene" includes a straight or branched alkylene group having one to six carbon atom(s), and for example, -CH2-, -CH(CH3)-, -C(CH3)2-, -CH2CH2-, -CH(CH3)CH2-, -C(CH3)2CH2-, -CH2CH2CH2-, -CH2CH2CH2CH2-, -CH2CH2CH2CH2CH2- and -CH2CH2CH2CH2CH2CH2- are exemplified. Preferably, -CH2-, -CH2CH2-, -CH2CH2CH2- and -CH2CH2CH2CH2- are exemplified. In the present specification, a term of "alkylene optionally containing one or two heteroatom(s)" of "optionally sunstituted alkylene optionally containing one or two heteroatom(s)' includes a straight or branched alkylene group having one to six carbon atoms, optionally containing one or two heteroatom(s) which may be substituted with "alkyl" above, and for example, -CH2-, -CH2CH2-, -CH2CH2CH2-, -CH2CH2CH2CH2", -CH2CH2CH2CH2CH2-, -CH2CH2CH2CH2CH2CH2-, -CH2O-, -OCH2-, -CH2CH2O-, -OCH2CH2-, -CH2S-, -S CH2-, -CH2CH2S-, -SCH2CH2-, -CH2CH2OCH2CH2-, -OCH2CH2O-, -OCH2O-, -NHCH2-, -N(CH3)CH2-, -N+(CH3)2CH2-, -NHCH2CH2CH2- and -N(CH3)CH2CH2CH2- etc. are exemplified. Preferably, -CH2-, -CH2CH2-, -CH2CH2CH2-, -CH2CH2CH2CH2-, -OCH2CH2O-, -OCH2O- and -N(CH3)CH2CH2CH2- are exemplified. CH2C=CCH2NH-, -NHCH2C=CH-, -CH2C=CCH2N(CH3)- and -N(CH3)CH2CsCH-are exemplified. Especially, -CH2C=CCH2- and -OCH2C=CH- are preferred. In the present specification, a term of "nitrogen-containing non-aromatic heterocyclic ring " includes a 3- to 12-mem-bered non-aromatic heterocyclic ring containing one or more of nitrogen atom(s), and further optionally containing an oxygen atom and/or a sulfur atom, and a formula of In the present specification, a term of "nitrogen-containing aromatic heterocyclic ring" includes a 3- to 12-rQembered aromatic heterocyclic ring containing one or more of nitrogen atom(s), and further optionally an oxygen atom and/or sulfur atom in the ring. For example, pyrrolyl(e.g., l-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl), imidazolyl(e.g., 2-imida2olyl, 4-imidazolyl), pyrazolyl(e.g,j 1-pyrazolyl, 3-pyrazolyl), isothiazolylfe.g., 3- In the present specification, examples of substituents in "optionally substituted alkyl", "optionally substituted cycloalkenylsulfonyloxy", "optionally substituted alkenyloxycarbonyl", "optionally substituted C1-C6 alkylene", "optionally substituted alkylene", "optionally substituted alkenylene" and "the optionally substituted alkynylene" include alkyl optionally substituted with a substituent group D at one to three position{s), cycloalkyl, alkylene optionally containing one or two heteroatom(s), hydroxy, oxo, alkyoxyl optionally substituted with a substituent group A at one to three position(s), mercapto, alkylthio, a halogen atom, nitro, cyano, carboxy, alkyloxycarbonyl, optionally substituted amino, optionally substituted carbamoyl, acyl acyloxy, aryl optionally substituted with a substituent group B at one to three position(s) (e.g., phenyl), heteroaryl optionally substituted with a substituent group C at one to three position(s) (e.g., pyridyl, furyl, thienyl, imidazolyl, oxazolyl, thiazolyl, pyrazolyl), non-aromatic heterocyclic group optionally substituted with a substituent group C at one to three position(s) (e.g., morpholinyl, pyrrolidinyl, piperajzinyl), axyloxy optionally substituted with a substituent group C at one to three position(s) (e.g., phenyloxy), alkylsulfonyl and the like. These can be substituted with one or more substituent(s) at any possible position. In the present specification, examples of substituents in "optionally substituted aryl", "optionally substituted phenoxy", "optionally substituted aryloxy", "optionally substituted phenylthio", "optionally substituted arylthio", "optionally substituted arylsulfinyl", "optionally substituted arylsulfonyl", "optionally substituted arylsulfonyloxy", "optionally substituted heteroaryl", "optionally substituted heteroaryloxy", "optionally substituted heteroarylthio", "optionally substituted heteroarylsulfmyl", "optionally substituted heteroarylsulfonyl", "optionally substituted heteroarylsulfonyloxy" and "optionally substituted non-aromatic heterocyclic group" include alkyl optionally substituted with a L3, k, n and q are the same as 1) above; La is a halogen atom or a hydroxy group; Lb is a hydrogen atom, a halogen atom, a hydroxy group, methylsulfonyloxy, p-toluenesulfonyloxy or tert-butyloxycarbonyl. A starting compound of the formula (VI) is available from commercial products or by chemical modification of the substituent on the compound of the formula (VI) such as general alkylation, esterification, amidation, hydrolysis, reductive reaction, oxdative reaction, Suzuki-coupling reaction, protection and de-protection reaction and the like. Step 1 is a process in which a compound of the formula (VI) is reacted with a compound of the formula (VII) to give a compound of the formula (VIII). The reaction can be carried out by reacting 0.5 to 5 equivalents of the compound (VII) compared to the compound (VI) in a solvent at 0°C to 150°C for 5 minutes to 48 hours. The reaction may be conducted under the presence of 1 to 5 equivalents of a base. Examples of the preferable base include sodium hydride, potassium carbonate, sodium carbonate, potassium bicarbonate, sodium bicarbonate, triethylamine and the like. Examples of the preferable solvent include tetrahydrofuran, N,N-dimethylformamide, dimethylsulfoxide, water and the like, which can be used alone or as a mixed solvent. solvent at 0°C to 150°C for 5 minutes to 48 hours. The reaction may be conducted under the presence of 1 to 5 equivalent(s) of a base. Examples of the preferable base include sodium hydride, potassium carbonate, sodium carbonate, potassium bicarbonate, sodium bicarbonate, triethylamine and the like. Examples of the preferable solvent include tetrahydrofuran, N,N-dimethylformamide, dimethylsulfoxide, water and the like, which can be used alone or as a mixed solvent. Step 2 is a process in which a compound of the formula (XII) is reacted with a compound of the formula (XIII), and the product is hydrolyzed under basic condition if necessary, to give a compound of the formula (XIV). The reaction can be carried out by reacting 0.5 to 5 equivalents of the compound (XIII) compared to the compound (XII) in a solvent at 0°C to 150°C for 5 minutes to 48 hours. Examples of the preferable solvent include ethyl acetate, methylene chloride, tetrahydrofuran, N,N-dimethylformamide, methanol, dioxane, water and the like, which can be used alone or as a mixed solvent. formula (XVI). The reaction can be carried out by reacting 0.5 to 5 equivalents of the compound (XV) compared to the compound (X) in a solvent at O°C to 150°C for 5 minutes to 48 hours. The reaction may be conducted under the presence of 1 to 5 equivalent(s) of a base. Examples of the preferable base include sodium hydride, potassium carbonate, sodium carbonate, potassium bicarbonate, sodium bicarbonate, triethylamine and the like. Examples of the preferable solvent include tetrahydrofuran, N,N-dimethylformamide, dimethylsulfoxide, water and the like, which can be used alone or as a mixed solvent. When Lb is tert-butyloxycarbonyl, the compound can be de-protected in a solvent such as ethyl acetate etc. at 0°C to 150°C for 5 minutes to 48 hours using hydrochloric acid. Step 2 is a process in which a compound of the formula (XVI) is condensed with a compound of the formula (XVII) to give a compound of the formula (XVIII). The reaction can be carried out by reacting 0.5 to 5 equivalents of the compound (XVII) compared to the compound (XVI) in a solvent at 0°C to 150°C for 5 minutes to 48 hours. Examples of the preferable solvent include ethyl acetate, methylene chloride, tetrahydrofuran, N,N-dimethylformamide, methanol, dioxane, water and the like, which can be used alone or as a mixed solvent. If necessary, 0.5 to 5 equivalents of l,l'-(azodicarbonyl)dipiperidine and tributylphosphine compared to the compound of the formula (XVI) can be used as a condensing agent. Step 3 is a process in which a compound of the formula (XVIII) is condensed, and if necessary further reduced and/or hydrolyzed under a basic condition to give a compound of the formula (XIX). The condensation reaction can be carried out by reacting 0.5 to 5 equivalents of a condensing agent compared to the compound (XVIII) in a solvent at O°C to 150°C for 5 minutes to 48 hours. Examples of the preferable solvent include ethyl acetate, methylene chloride, tetrahydrofuran, N,N-dimethylformamide, dimethylsulfoxide, water and the like, which can be used alone or as a mixed solvent. chromatography and re-crystallization etc. In addition, a compound of the genaral formula (X) can be prepared by the next method; n wherein the ring A, R3, R4 and q are the same as 1) before, and W3 is a halogen atom. In a method for preparing the compound of the formula (X) from the compound of the formula (XX), the compound of the formula (XX) is 1) converted to a SO3H derivative by treating with CISO3CI, and 2) followed by chlorination of the hydroxy group by the reaction with POCI3 or PCI5 to give the compound of the formula (X). In a method for preparing the compound of the formula (X) from the compound of the formula (XXI), the compound of the formula (XIX) is 1) lithiated by n-BuLi, and 2) follwed by conversion to a S02Li derivative by the reaction with SO2, and finally 3) reacted with SO2CI2 to give the compound of the formula (XX). A bromine atom or an iodine atom is preferable as W3. In addition, each substituent may be converted to the other substituent in each step using a general reaction such as alkylation, esterification, amidation, hydrolysis, reductive reaction, oxdative reaction, Suzuki-coupling reaction and the like. In this specification, a term of "solvate" includes, for example, a solvate with an organic solvent, a hydrate and the like. In a case of forming the solvate with an organic solvent, any number of molecules of the organic solvent may coordinated. In a case of forming the hydrate, any number of water molecules may be coordinated. A hydrate is usually preferred. A term of "compound of the present invention" includes a pharmaceutically acceptable salt and a solvate thereof. Examples of the salt include salts with alkaline metal{lithium, sodium and potassium etc.), alkaline earth raetal(magnesium and calcium etc.)-, ammonium, organic bases and amino acids and salts with inorganic acids(hydrochloric acid, hydrobromic acid, phosphoric acid and sulfuric acid, ration through a powder, granule, tablet, capsule, pill, liquid formulation and the like, or parenteral administration through an injection, suppository, transdermal formulation, inhalant and the like is possible. A pharmaceutical composition can be obtained by mixing a therapeutically effective amount of a compound of the present invention with a pharmaceutical additives such as an excipient, binder, wetting agent, disintegrating agent, lubricant and the like, which is suitable to the selected formulation. An injection can be formulated by sterilization together with a suitable carrier. In the treatment of the diseases related to PGD2 receptor above, it is possible to use the compound of the present invention combined with or in a coupled formulation with the other therapeutic agent. In the case of treating inflammatory diseases including allergy, the compound can be used combined with or in a coupled formulation with leukotriene receptor antagonist(e.g., montelukast sodium, zafirlukast, pranlukast hydrate, leukotriene B4 receptor antagonist); leukotriene synthesis inhibitor such as zileuton, PDE IV inhibitor(e,g., theophylline, cilom.ilast, roflumilast), corticosteroid(e.g., prednisolone, fluticasone, budesonide, ciclesonide), (32-agonist(e.g., salbutamol, salmeterol, formoterol), anti IgE antibody(e,g., omalizumab), histamine HI receptor antagonist(e.g., chlorpheniramine, loratadine, cetirizine), immunosuppressant(tacrolimus, cyclosporin), thromboxane A2 receptor antagonist(e.g,, ramatroban), chemokine receptor(especially CCR-1, CCR-2, CCR-3) antagonist, other prostanoid receptor antagonist(e,g,, CRTH2 antagonist), adhesion molecule antagonist(e,g., VLA-4 antagonist), cytokine antagonist(e.g., anti-IL-4 antibody, anti-IL-3 antibody), Non-steroidal anti-inflammatory agent(e.g., propionic acid derivative such as ibuprofen, ketoprofen, and naproxen etc.; acetic acid derivative such as indomethacin, and diclofenac etc.; salicyic acid such as acetyl salicylic acid; cyclooxigenase-2 inhibitor such as celecoxib and etoricoxib). Further, uses combined with or in a coupled formulation with antitussive agent(e.g., codein, hydrocodein), cholesterol lowering agent(lovastatin, simvastatin, fluvastatin. rosuvastatin), anticholinergic drug(e.g., tiotropium, ipratropium, flutropium, oxitropium) are also possible. step 1 4-Isopropoxybenzenesulfonyl chloride(2.34 g, 10.0 mmol) and triethylainine(4.2 mL, 30.0 mmol) were added at 0°C to a solution of 4-hydroxypiperidine(1.01 g, 10.0 mmol) in THF(20 mL) and the mixture was stirred for an hour. Diluted hydrochloric acid (60 mL) and ethyl acetate(60 mL) were added to the reaction solution, the mixture was extracted and the organic layer was washed with a saturated aqueous solution of sodium bicarbonate and saturated brine successively, dried and concentrated. n-Hexane was added to the residue and the resulting crystalline was filtered to give the compound (2) (2.8 g, 94% yield). 1 H-NMR(CDCl3) 6ppm:1.36 (d, J - 6.0 Hz, 6H), 1.71 (m, 2H), 1.93 (m, 2H), 2.84 (m, 2H), 3.23 (m, 2H), 3.77 (m, 1H), 4.06 (m, 1H),6.95 (d, J = 8.7 Hz, 2H), 7.66 (d, J = 8.7 Hz, 2H). Step 2 Carboethoxymethylenetriphenylphosphorane(920 mg, 2.6 mmol) was added to a solution of 2-hydroxy-4-methylbenzaldehyde(3) (300 mg, 2.2 mmol) in THF(5 mL) and the mixture was heated under reflux for an hour. After the reaction mixture was cooled down, the solvent was evaporated. The resulting residue was purified by a silica gel column chromatography(hexane:ethyl acetate = 5:1) and concentrated to give the compound(4) (320 mg, 70% yield). 1H-NMR(CDCl3)5ppm:1.34(t, J = 7.2Hz, 3H), 2.28 (s, 3H), 4.27 (m, 2H), 6.09 (s, 1H), 6.60 (d, J = 16.2 Hz, 1H), 6.74 (d, J = 8.1 Hz, 1H), 7.04 (dd, J = 2.1, 8.1 Hz, 1H), 7.27 (d, J = 2.1 Hz, 1H), 8.00 (d, J = 16.2 Hz, 1H). Step 3 The coinpound(2) (218 mg, 0.7 mmol) obtained in step 1, 1,1'-(azodicarbonyl) dipiperidine(238 mg, 0.9 mmol) and tribu1ylphosphine(0.57 mL, 2.2 mmol) were added to a solution of the compound(4) (150 mg, 0.7 mmol) in THF(10 mL), and the mixture was stirred at room temperature for 4 hours. Water was added to the reaction solution, the mixture was extracted with ethyl acetate and the organic layer was washed with a saturated aqueous solution of sodium bicarbonate and saturated brine successively, dried and concentrated. The resulting residue was purified by a silica gel column chromatography(hexane:ethyl acetate = 3:1) to give the compound(5) (130 mg, 37% yield). step 1 4-Isopropoxybenzenesulfonyl chloride(2.35 g, 10.0 mmol) and triethylainine(3.7 mL, 22.0 mmol) were added to a solution of bis(2-chloroethyl)amine hydrochloride(6) (1.78 g, 10.0 mmol) in DMF(20 mL) and the mixture was stirred at room tem.perature for 2 hours. Diluted hydrochloric acid{200 mL) was added to the reaction solution, the mixture was extracted with ethyl acetate(200 mL) and the organic layer was washed with a saturated aqueous solution of sodium bicarbonate and saturated brine successively, dried and concentrated. The resulting residue was purified by a silica gel column chromatography(hexane:ethyl acetate = 8:1) to give the compound(7) (1.79 g, 53% yield). 1H-NMR(CDCl3) 5 ppm: 1.37 (d, J = 6.3 Hz, 6H), 2.98 (m, 4H),3.74 (m, 4H), 4.64 (m, 1H), 6.97 (d, J = 9.0 Hz, 2H), 7.66 (d, J = 9.0 Hz, 2H). Step 2 , 3.81 (s, 3H), 4.65 (s, 3H), 6.28-6.34 (m, 2H), 6.73 (d, J = 8.4 Hz, 1H). Step 4 The compound(7) (749 mg, 2.2 mmol), potassium carbonate( 1.11 g, 8.0 mmol) and potassium iodide(66.4 mg, 0.4 mmol) were added to a solution of the compound(lO) (422 mg, 2.0 mmol) in DMF(5 mL) and the mixture was stirred at room temperature for 18 hours. Diluted hydrochloric acid(50 mL) was added to the reaction solution and the mixture was extracted with ethyl acetate(50 mL), and the organic layer was washed with a saturated aqueous solution of sodium bicarbonate and saturated brine, dried and concentrated. The resulting residue was purified by a silica gel column chromatography(hexane:ethyl acetate = 2:1) to give the compound 111-1(43 mg, 5% yield) 1H-NMR(CDCl3) 5 ppm: 1.37 (d, J = 6.0 Hz, 6H), 3.15 (brs, 8H), 3.78 (s, 3H), 3.83 (s, 3H), 4.60 (m, 1H), 4.65 (s, 2H), 6.60-6.63 (m, 2H), 6.81 (d, J = 7.8 Hz, 1H), 6.96 (d, J = 9.0 Hz, 2H), 7.69 (d, J = 9.0 Hz, 2H). Step 5 The compound 111-1(40 mg, 0.084 mmol) was dissolved in MeOH(1.0 mL) and THF(1.0 mL). A 2M aqueous solution of sodium hydroxide(0.12 mL, 0.25 mixture was stirred at room temperature for 2 hours. Diluted hydrochloric acid(200 mL) was added to the reaction solution and the mixture was extracted with ethyl acetate(200 mL), and the organic layer was washed with a saturated aqueous solution of sodium bicarbonate and saturated brine succesively, dried and concentrated. The residue was crystallized from hexane-ethyl acetate to give the compound(12) (6.78 g, 88% yield) 1H-NMR(CDCl3) 5 ppm: 1.37 (d, J - 6.0 Hz, 6H), 1.41 (s, 9H), 2.95 (m, 4H), 3.51 (m, 4H), 4.63 (m, 1H), 6.96 (d, J = 8.7 Hz, 2H), 7.65 (d, J = 8.7 Hz, 2H). Step 2 A 4M solution-of hydrochloric acid in ethyl acetate was added to a solution of the compound(12) (6.78 g, 17.5 mmol) in ethyl acetate(30 mL) and the mixture was stirred at room temperature for 2 hours and the stirring was further continued at 50°C for 1 hour. Water(200 mL) was added to the reaction solution and extracted with ethyl acetate(200 m.L). After the aqueous layer was adjusted to pH=l 1 by adding a 2M aqueous solution of sodium hydroxide, the mixture was extracted with ethyl acetate(400 mL). The organic layer was washed with water and saturated brine successively, dried and concentrated. The residue was crystallized from hexane-ethyl acetate to give the compound(13) (4.58 g, 92% yield). 1 H-NMR(CDCl3) 6 ppm: 1.37 (d, J = 6.0 Hz, 6H), 2.95 (m, 8H),4.63 (m, 1H), 6.94 (d, J = 8.7 Hz, 2H), 7.65 (d, J = 8.7 Hz, 2H). Step 3 bicarbonate and saturated brine successively, dried and concentrated. The resulting residue was purified by a silica gel colum.n chromatography(hexane:ethyl acetate = 3:1) and concentrated to give the residue, which was used in the next step without further purification. 1H-NMR(CDCl3) 5 ppm: 1.37 (d, J = 6.0 Hz, 6H), 3.17 (brs, 8H), 4.63 (m, 1H), 4.70 (s, 2H), 6.87 (dd, J = 2.4, 7.8 Hz, 1H), 6.96 (d, J = 9.0 Hz, 2H), 7.09 (m, 1H), 7.28-7.34 (m, 5H), 7.68 (d, J = 9.0 Hz, 2H), 8.08 (dd, J = 1.5, 4.8 Hz, 1H). Step 5 To the residue obtained in the step 4 were added THF(2 mL) and MeOH(2 mL), and further 10% palladium carbon(150 mg), and the mixture was stirred under hydrogen atmosphere at room temperature for 1.5 hours. The reaction solution was filtered through Celite and the filtrate was concentrated. The residue was crystallized from hexane-ethyl acetate to give the compound(17) (365 mg, 57% yield/two steps). 1H-NMR(CDCl3) 5 ppm: 1.37 (d, J = 6.0 Hz, 6H), 3.25 (m, 8H),4.63 (m, 1H), 6.26 (m, 1H), 6.94-7.04 (m, 4H), 7.67 (d, J = 8.7 Hz, 2H). Step 6 Ethyl iodoacetate(0.95 mL, 0.8 mmol) and silver carbonate(165 mg, 0.6 mmol) were added to a solution of the compound(17) (151 mg, 0.4 mmol) in ' toluene(20 mL) and the mixture was heated under reflux for 3 hours under nitrogen atmosphere. After being cooled, the reaction solution was filtered through a glass filter. The filtrate was concentrated and the resulting residue was purified by a silica gel column chromatography(hexane:ethyl acetate = 5:1) to give the compound 111-2(83 mg, 45% yield). stirred for 0.5 hours. Thereto was added chloromethyl methyl ether(3.4 mL, 45.0 mmol) dropwise at 0°C and the mixture was stirred at room temperature for an hour. Water(300 mL) was added to the reaction solution and extracted with diethyl ether(300 m.L). The extract was washed with water and saturated brine successively, dried and concentrated to give the compound(19) (6.6 g, 99% yield) 1H-NMR(CDCl3) 5 ppm:3.52 (s, 3H), 5.25 (s, 2H), 6.89 (m, 1H), 7.13-7.28 (m, 2H), 7.55 (m, 1H). step 2 A solution of the compound( 19) (2.17g, 10.0 mmol) in THF(125 mL) was cooled to -78°C, thereto was added a hexane solution of n-butyl lithium(7.5 mL, 12,0 mmol) dropwise during 10 minutes and the mixture was stirred at the same temperature for 30 minutes. The solution was warmed up to -50°C, a solution of l-(tert-butoxycarbonyl)piperidone(3.79 g, 19.0 mmol) in THF(100 mL) was added dropwise at -50°C and then the mixture was stirred at -20°C for 30 minutes. A saturated aqueous solution of NH4 Cl(300 mL) was poured to the reaction solution and the mixture was extracted with diethyl ether(300 mL). The extract was washed with water and saturated brine successively, dried and concentrated. The resulting residue was purified by a silica gel column chromatography(hexane:ethyl acetate = 2:1) to give the compound(20) (650 mg, 19% yield). brine successively, dried and concentrated. The resulting residue was purified by a silica gel column chromatography[hexane:ethyl acetate = 5:1) to give the compound(22) (150 mg, 21% yield/two steps). 1H-NMR(CDCl3) 5 ppm:1.37 (d, J=6.3 Hz, 6H), 2.33 (m, 2H), 3.35 (t, J=5.7 Hz, 2H), 3.77 (m, 2H), 4.64 (m, 1H), 5.79 (m, 1H), 6.83-7.00 (m, 5H), 7.14 (m, 1H), 7.73(d, J=9.0Hz, 2H). Step 5 e was crystallized from hexane-ethyl acetate to give the compound 111-4(62 mg, 99% yield). Step 8 The compound 111-4(52 mg, 0.138 mmol) was dissolved in MeOH(1.0 mL) and THF(1.0 mL). A 2M aqueous solution of sodium hydroxide(207 µL) was added and the solution was stirred at room temperature for 2 hours. The reaction solution was diluted with water, acidified by adding diluted hydrochloric acid and extracted with ethyl acetate. The extract was washed with water, dried and concentrated. The residue was crystallized from hexane-ethyl acetate to give the compound 1-4(20 mg, 33% yield). 1H-NMR(DMS0-d6) δppm:1.32 (d, J = 6.0 Hz, 6H), 1.60-1.71 (m, 2H), 1.82 (d, J = 11.7 Hz, 2H), 2.26 (t, J = 10.5 Hz, 2H), 2.84 (t, J = 11.7 Hz, 1H), 3.75 (d, J = 11.4 Hz, 2H), 4.64 (s, 2H), 4.72-4.80 (m, 1H), 6.80 (d, J = 8.4 Hz, 1H), 6.90 (t, J = 7.2 Hz, 1H), 7.11-7.15 (m, 4H), 7.67 (d, J = 8.7 Hz, 2H), 13.00 (brs,lH). p 3 in THF(10.0 mL) was cooled to 0°C, and triethylamine(4.2 mL, 30.0 mmol) and 4-isopropoxybenzenesulfonyl chloride(2.58 g, 11.0 mmol) were added thereto. After stirring at room temperature for 15 hours, the reaction solution was poured into water and extracted with ethyl acetate. The organic layer was washed with 2N hydrochloric acid, water and saturated brine successively, and dried over anhydrous magnesium sulfate. The solvent was evaporated in vacuo to give the product 111-13(4.17 g, 85% yield) as a yellow powder. Step 5 A 2M aqueous solution of sodium hydroxide(0.60 mL, 1.2 mmol) was added to a solution of the compound 111-13(197 mg, 0.40 mmol) obtained in step 4 in MeOH(2.0 mL)-THF(2.0 mL) and stirred at room temperature for 2 hours. The reaction solution was poured into water and washed with ether. The aqueous layer was acidified by adding 2N hydrochloric acid, an extracted with ethyl acetate. The organic layer was washed with water, dried over anhydrous magnesium sulfate and concentrated in vacuo. The crude cry'stalline was re-cystallized from hexane-ethyl acetate to give the product 11-13(166 mg, 87% yield) as a yellow powder. 1H-NMR(CDCl3) 5 ppm: 1.37 (d, 6H, J = 6.3 Hz), 3.15 (brt, 4H, J = 4.8 Hz), 3.50 (brt, 4H, J = 4.2 Hz), 4.60-4.70 (m, 1H), 4.75 (s, 2H), 6.24, (s, 1H), 6.49 (dd, 1H, J = 2.1, 9.3 Hz), 6.98 (d, 2H, J = 9.0 Hz), 7.69 (d, 2H, J = 8.7 Hz), 8.06 (d, 2H, J = 9.6 Hz). hrough Celite and the filtrate was concentrated in vacuo. The resulting crude crystalline was washed with ether to give the product(28) (5.00 g, 77% jdeld) as a purple powder. Step 3 A solution of the compound(28) (1.17 g, 3.0 mmol) obtained in step 2 in pyridine(5.0 mL) was cooled to 0°C and 2-furilic acid chloride(0.28 mL, 2.85 mmol) was added thereto. After stirring at room temperature for 18 hours, the reaction solution was poured into water and extracted with ethyl acetate. The organic layer was washed with a 0.5M citric acid solution and water, and dried over anhydrous magnesium sulfate. The solvent was evaporated in vacuo to give the product(29) (660 mg, 45% yield) as a purple powder. Step 4 Potassium carbonate(370 mg, 2.68 mmol) and methyl bromoacetate(0.19 mL, 2.01 mmol) were added to a solution of the compound(29) (650 mg, 1.34 mmol) obtained in step 3 in DMF(5.0 mL) and stirred at room temperature for 2 hours. The reaction solution was poured into water and extracted with ethyl acetate. The organic layer was washed with a 0.5M citric acid solution and water, dried over anhydrous magnesium sulfate and concentrated in vacuo. The residue was purified by a silica gel column chromatography(chloroform:methanol = 500:1) and the crude crystalline obtained was re-crystallized to give the compound 111-24(360 mg, 48% yield) as a pale purple powder. Step 5 A 2M solution of sodium hydroxide(2.39 mL, 4.77 mmol) was added to a solution of the compound III-24 (350 mg, 1.59 mmol) obtained in step 4 in MeOH(3.5 mL)-THF(3.5 mL) and stirred at room temperature for 2 hours. The reaction solution was poured into water and washed with ether. 2N Hydrochloric acid was added to the aqueous layer and the precipitated crystalline was collected by filtration. The obtained crude crystalline was re- irred at room temperature for 18 hours. The reaction solution was cooled to 0°C and an aqueous solution(10.0 mL) of sodium nitrate(3.37 g, 48.8 mmol) was added dropwise during 20 minutes. Then, an aqueous solution(10.0 mL) of potassium iodide(9.96 g, 61.0 mmol) was added dropwise during 20 minutes. After stirring at 0°C for an hour, the reaction solution was extracted with ether. The organic layer was washed with a saturated aqueous solution of sodium thiosulfate and water and dried over anhydrous magnesium sulfate. The solvent was evaporated in vacuo to give the product(32) (5.00 g, 65% yield). Step 3 A solution of the compound(32) (5.00 g, 16.0 mmol) obtained in step 2 in dichloromethylane(10.0 mL) was cooled to 0°C and a IM solution of boron tribromide in dichloromethylane(32.0 mL) was added dropwise during 30 minutes. After stirring at 0°C for an hour, it was stirred at room temperature for 3 hours. The reaction solution was poured into ice-water, concentrated hydrochloric acid was added and the mixture was stirred at room temperature for an hour. The mixture was extracted with ether and the organic layer was extracted with a 2M aqueous solution of sodium hydroxide. The aqueous layer was acidified by adding 2N hydrochloric acid and extracted with ethyl acetate. The organic layer was washed with water and dried over anhydrous magnesium sulfate. The solvent was evaporated in vacuo to give the product(33) (4.30 g, 90% yield) und(34) (686 mg, 2.0 mmol) obtained in step 4 in toluene(3.4 mL) and stirred at 50°C for 4 hours. The reaction solution was poured into water and extracted with ethyl acetate. The organic layer was washed with water, dried over anhydrous magnesium sulfate and concentrated in vacuo. The residue was purified by a silica gel column chromatography(ethyl acetate:hexane = 2:1) and the cnade Crystalline was re-crystallized to give the product(35) (412 mg, 41% yield). Step 6 2N Hydrochloric acid was added to a solution of the compound(35) (300 mg, 0.60 mmol) obtained in step 5 in MeOH(2.0 mL)-THF(2.0 mL) and stirred at room temperature for 18 hours. The reaction solution was poured into water and extracted with ethyl acetate. The organic layer was washed with water, and concentrated in vacuo. The resulting residue was dissolved in ether and extracted with a 2M aqueous solution of sodium hydroxide. The aqueous layer was acidified by adding 2N hydrochloric acid and extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was evaporated in vacuo to give the product(36) (179 mg, 56% yield) as a colorless powder. The aqueous layer was acidified by adding 2N hydrochloric acid and extracted with ethyl acetate. The organic layer was washed with water, dried over anhydrous magnesium sulfate and concentrated in vacuo. The obtained crude crystalline was re-crystallized from ethyl acetate/hexane to give the product II-33 (142 mg, 97% jdeld) as a colorless powder. 1 H-NMR(DMS0-d6) δ ppm:1.30 (d, J = 6.0 Hz, 6H), 2.95 (brs, 4H), 3.02 (brs, 4H), 4.71-4.79 (m, 3H), 6.42 (dd, J = 2.4, 9.0 Hz, 1H), 6.54 (d, J = 2.4 Hz, 1H), 7.13 (d, J = 9.0 Hz, 2H), 7.32 (d, J = 8.7 Hz, 1H), 7-66 (d, J = 8.7 Hz, 2H). m carbonate(87.3 g, 0.63 mmol) and methyl bromoacetate(0.036 mL, 0.38 mmol) were added to a solution of the compound(38) (140 mg, 0.32 mmol) obtained in step 2 in DMF(2.0 mL) and stirred at room tem.perature for 18 hours. The reaction solution was poured into water and extracted with ethyl acetate. The organic layer was washed with 2N hydrochloric acid and water, and dried over anhydrous magnesium sulfate. The solvent was evaporated in vacuo to give the product 111-54(110 mg, 68% yield) as a colorless powder. Step 4 A 2M solution of sodium hydroxide(0.29 mL, 0.58 mmol) was added to a solution of the compound 111-54(100 mg,0.19 mmol) obtained in step 3 in chromatography(ethyl acetate/hexane = 1/10), and the obtained crude product was re-crystallized from hexane to give the product(40) (3.95 g, 44% yield) as a white powder. Step 2 A solution of the compound(40) (1.8 g, 6.48 mmol) obtained in stepl, the compound(13) (2.03 g, 7.12 mmol) obtained in step 2 of Example 3, palladium acetate(58 mg, 0.26 mmol), rac-2,2'-bis(diphenylphosohino)-l,l'-binaphthyl(242 mg, 0.39 mmol) and cesium carbonate(2.95 g, 9.07 mmol) in toluene(20 mL) was stirred at 100°C under nitrogen atmosphere for 12 hours. After being cooled to room tem.perature, the reaction solution was extracted with chloroform. The organic layer was washed with water and 2N hydrochloric acid, and concentrated in vacuo. The residue was crystallized from ethanol-chloroform to give the product(41) (1.35 g, 48% jdeld). Step 3 A solution of the compound(41) (380 m.g, 0.875 mmol) obtained in step 2, potassium t-butoxide(980 mg, 8.75 mmol) and water(63 µL, 3.5 mmol) in THF(5 mL) was stirred at room temperature for 1.5 hours. The reaction solution was extracted with ethyl acetate and the organic layer was washed with water, 2N hydrochloric acid and saturated brine. The solvent was evaporated in vacuo and the residue was crystallized from ethyl acetate-hexane to give the product(42) (353 mg, 96% yield). Step 4 A solution of the compound(42) (250 mg, 0.59 mmol) obtained in step 3, WSCD HC1(137 mg, 0.71 mmol), HOBt(97 mg, mmol), isopropylamine(61 µL, 0.71 mmol) in DMF(2 mL) was stirred at room temperature for 2 hours. The reaction solution was extracted with ethyl acetate and the organic layer was washed with water and 2N hydrochloric acid. The solvent was evaporated in vacuo and the residue was purified by a silica gel column chromatograph3-'(ethyl acetate/hexane = 1/4) to give the product(43) (177 mg, 64% yield). Step 5 shed 'with saturated brine and the solvent was evaporated in vacuo. A solution of the resulting solid, potassium carbonate(18.0 g, 130.23 mmol) and benzyl bromide(19.20 g, 112.25 mmol) in DMF(50 mL)-ethyl acetate(50 mL) was stirred at 60°C for 2 hours. Water was added to the reaction solution and the reaction solution was extracted with ethyl acetate. The organic layer was washed with saturated brine and the solvent was evaporated in vacuo. The obtained crystalline was washed with 10% ethyl acetate-hexane to give the product(45) (23.40 g, 76% yiled). Step 2 2N Hydrochloric acid(15 m.L) was added to a solution of the compound(45) (5.0 g, 14.29 mmol) obtained in step 1 in TH (20 mL) and stirred at 70°Cfor 2 hours. After being cooled to room temperature, the reaction mixture was extracted with ethyl acetate, the organic layer was washed with saturated brine and the solvent was evaporated in vacuo. Acetonitrile(15 mL) was added to the resulting residue and the solution was used in the next step. A solution of triphenylphosphine(7.45 g, 28.40 mmol) and hexachloroethane(6.72 g, 28.40 mmol) in acetonitrile was stirred for 30 minutes, the solution of the obtained residue in acetonitrile(15 mL) and pyridine(4.6 mL, 56.80 mmol) were added thereto and the mixture was stirred at room temperature for 30 minutes. Further, it was stirred at 60°C for a hour. Water was added to the reaction solution and the reaction solution was extracted with ethyl acetate. The organic layer was washed with water and 10% aqueous solution of citric acid, and the solvent was evaporated in vacuo. The residue was purified by a silica gel column chromatography(ethyl acetate/hexane = 1/4) to give the product(46) (3.35 g, 83% yield). Step 3 A solution of the compound(46) (200 mg, 0.70 mmol) obtained in step 2, ater(5.0 mL) were added. The obtained crystalline was collected by filtration to give the product 111-74(212 mg, 91% yield) as a white crystalline. Step 5 A solution of the compound 111-74(65 mg, 0.126 mmol) obtained in step 5 and 4N aqueous solution of sodium hydroxide(80µ L, 0.315 mmol) in DMF(1 mL) was stirred overnight. After 2N hydrochloric acid(315 µ L)was added to the reaction solution and stirred, water(20. mL) was added to the reaction mixture and stirred at 0°C for 30 minutes. The precipitated crystalline was collected by filtration to give the product 11-74(50.6 mg, 80% yield) as a white crystalline. 1H-NMR(CDCl3) 5 ppm:1.37 (d, 6H, J = 6.0 Hz), 3.16 (t, 4H), 3.42 (t, 4H), 4,63 (m, IH), 4.77 (s, 2H), 6.40 (d, 1H, J = 2.7 Hz), 6.62 (dd, 1H, J = 9.0 Hz, 2.4 Hz), The reaction solution was cooled to room temperature, and water was added. The reaction solution was extracted with chloroform, the organic layer was washed with water, dried over anhydrous magnesium sulfate and concentrated in vacuo. The residue was re-crystallized from hexane to give the product(51) (22.9 g, 97% yield) as a yellow powder. Step 3 Potassium carbonate(18.7 g, 50.0 mmol), potassium iodide(0.83 g, 5.0 mmol) and benzyl bromide(3.21 mL, 55.0 mmol) were added to a solution of the compound(51) (10.8 g, 50.0 mmol) obtained in step 2 in DMF(50.0 mL) and stirred at 60°C for 18 hours. After being cooled to room temperature, water was added to the reaction solution. The precipitated crystalline was collected by filtration and washed with water. The resulting crude crystalline was washed with hexane to give the product(52) (13.8 g, 90% yield). Step 4 lpiperazme(1.23 g, 4.33 mmol), tris(dibenzylideneacetone)dipalladium(152 mg, 0.17 mmol), rac-2,2'-bis(diphenylphosohino)-l,r-binaphthyl(414 mg, 0.57 mmol) and sodium t-butoxide(540 mg, 6.56 mmol) were added to a solution of the compound(54) (1.10 g, 3.33 mmol) obtained in step 5 in toluene(3.4 mL) and stirred at 100°C for 12 hours. Water was added to the reaction solution and extracted with ethyl acetate. The organic layer was filtered through Celite, washed with 2N hydrochloric acid and water, dried over anhydrous magnesium sulfate and concentrated in vacuo. The residue was purified by a silica gel column chromatography (ethyl acetate/hexane = 2/1) to give the product(55) (450 mg, 25% yield) as a yellow powder. Step 7 le 1 DP inhibitory activity in vitro 1) Preparation of platelet and a method of cAMP assay 30 mL of peripheral blood was collected from a healthy volunteer using a syringe containing one ninth amount of 3.8 % sodium citrate. After being centrifuged at 180 g for 10 minutes at room temperature, a supernatant was collected and used as Platelet Rich Plasma(PRP). The resulting PRP was washed with wash buffer and centrifuged three times(Washed Platelet: WP) and platelets were counted by a m.icrocell counter. WP was added to a plate in amount of 1.5 x lO8/assay and the plate was treated with 3-isobutyl-l-methylxanthin(IBMX; 0.5 mM) for 5 minutes. A reaction was initiated by adding 100 nM of PGD2 5 min after an addition of a test compound. The reaction was terminated with an addition of IN hydrochloric acid after 2 minutes and the cells were destructed using 12 % triton X-100. An amount of cAMP in the supernatant was assayed by Homogeneous Trangient Fluore scence (HTRF) 2) Receptor Binding Assay A prepared WP was homogenated and a membrane fraction was collected with high-speed centrifugation. A compound of the present invention or a reference compound A(No, IC-73 in WO 2003/097598) was added to the plate and [3H]-PGD2 was also added. A platelet membrane, a protein concentration is 2 mg/mL, was added and mixed in the plate, and placed on ice for 2 hours. The reaction solution was transferred to a low protein-adsorptive filter and washed with a wash solution eight times using a cell harvester. After the final washing, water was removed sufficiently, and scintillator was added. DP inhibitory activity was investigated by measuring [3H] by using Micro Beta. 50% DP-inhibitoiy concentrations (IC50) in the cAMP assay and Ki values in the receptor binding assay were shown in Table 61. 3) Prostanoid agonist and antagonist assay Agonistic and antagonistic activities of the com.pounds of the present invention against prostanoid receptors were evaluated based on intracellular calcium flux or cAMP-production as an indicator using HEK 293 cells expressing human EPl, EP2, EP3, EP4, FP, TP and IP respectively. Any compounds did not show an agonistic activity against each prostanoid. In the other hand, more than twenty times potent antagonistic activity(IC50) was found in every compound compared with IC50 of cAMP assay with WP. mg/mL of ovalbumin(OVA) and 1 mg of aluminum hydroxide gel. A solution of 1% OVA was aerosolized by ultrasonic nebulizer(NE-U17) and the rats were subjected to inhalation exposure of the aerosol for 30 minutes in an exposing chamber 12, 19, 26 and 33 days after the sensitization. One hour before the 4th exposure of the antigen, compounds of the present invention were administered in a dose of 10 mg/kg p.o. once a day for three days consecutively. In a control group, 0.5% of methyl cellulose was administered in place of the compound of the present invention. Under pentobarbital anesthesia(80 mg/kg, i.p.), acetylcholine(3.9, 7.8, 15.6, 31.3, 62.5, 125, 250 and 500 µg/kg) was injected to jugular vein of the rats successively from a lower dose at intervals of 5 minutes three days after the fourth exposure to the antigen, and immediate contractile reaction of airways(an increase of insufflation pressure) was measured by a modified method of Konnzett & Rossler. Inhibition rate of airway hyperresponsiveness against the control group was calculated based on area under the curve(AUC) obtained from concentration-response curve of acetylcholine. After the measurement of increased hyperresponsive airway was completed, bronchoalveoli of the rats were washed with 5 mL of saline three times. Total cell number in the washings was counted by a hemacytometer under light microscope, and inhibition rates of infiltration of inflammatory cells against the control group were calculated. Further, mucin in the airway lavage fluid was measured by ELISA method using jacalin, a mucin-binding lectin, and the inhibition rates of mucus-secretion against the control group were calculated. Results were shown in Table 62. Test Example 3 Test using nasal congestion model of guinea pig Methods of measuring nasal airway resistance and evaluating anti-nasal congestion activity using a guinea pig were illustrated below. A 1% solution of ovalbumin(OVA) was aerosolized by ultrasonic nebulizer, male Hartley guinea pigs were sensitized by inhalation of the aerosol for 10 minutes twice at an interval of a week and a reaction was initiated by exposure to the antigen 7 days later. Trachea of the guinea pig was incised under pentobarbital anesthesia(30 mg/kg, i.p.), and cannulae were fitted at the sides of nasal cavity and lung respectively. To the lung side, a ventilator supplying 4 mL of air every time at a rate of 50 times/min was connected. Spontaneous breathing of the guinea pig was stopped by the administration of Formulation Example The following formulating examples 1-8 are just for illustrative purposes and not intended to limit the range of the present invention. A term of "active ingredient" means the compounds of the present invention, pharmaceutically acceptable salt or hydrate thereof. The active ingredient, starch and cellulose are put through a sieve of No. 45 mesh US and mixed sufficiently. The resulting powder is mixed with a solution containing polyvinylpyrrolidone and the mixture is put through a sieve of No. 14 mesh US. The granulated powder is dried at 50°C and put through a sieve of No. 18 mesh US. Sodium carboxymethylstarch, magnesium stearate and talc are put through a sieve of No.50 mesh US in advance and added to the granulated powder, m.ixed and compressed by a tableting machine to give a tablet weighing 150 mg/tablet. Formulation Example 5 CLAIMS wherein the ring A is an aromatic carbocyclic ring or an aromatic heterocyclic ring; the ring B is a nitrogen-containing non-aromatic heterocyclic ring or a nitrogen-containing aromatic heterocyclic ring; the ring C is an aromatic carbocyclic ring or an aromatic heterocyclic ring; R1 is hydroxyalkyl, carboxy, alkyloxycarbonyl, optionally substituted carbamoyl, or a carboxy equivalent; R2 is independently a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, hydroxy, optionally substituted alkyloxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted cycloalkyloxy, optionally substituted cycloalkenyloxy, mercapto, optionally substituted alkylthio, optionally substituted alkenylthio, optionally substituted alkynylthio, optionally substituted alkylsulfmyl, optionally substituted alkylsulfonyl, optionally substituted alkylsulfonyloxy, optionally substituted cycloalkylthio, optionally substituted cycloalkylsulfmyl, optionally substituted cycloalkylsulfonyl, optionally substituted cycloalkylsulfonyloxy, optionally substituted cycloalkenylthio, optionally substituted cycloalkenylsulfinyl, optionally substituted cycloalkenylsulfonyl, optionally substituted cycloalkenylsulfonyloxj^ optionally substituted amino, acyl, optionally substituted alkjdoxycarbonyl, optionally substituted alkenyloxycarbonyl, optionally substituted alk3aryloxycarbonyl, optionally substituted aryloxycarbonyl, optionally substituted carbamoyl, optionally substituted sulfamoyl, cyano, nitro, optionally substituted aryl, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted arylsulfinyl, optionally substituted arylsulfonyl, optionally substituted arylsulfonyloxy, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heteroarylthio, optionally substituted heteroarylsulfinyl, optionally substituted heteroarylsulfonyl, optionally substituted heteroarylsulfonyloxy or an optionally substituted non-aromatic heterocyclic group; R3 is a hydrogen atom, optionally substituted alkyloxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted cycloalkyloxy, optionally substituted cycloalkenyloxy, optionally substituted aryloxy, optionally substituted heteroaryloxy, optionally substituted alkylthio, optionally substituted alkenylthio, optionally substituted alkynylthiOj optionally substituted cycloalkylthio, optionally substituted cycloalkenylthio, optionally substituted arylthio or optionally substituted heteroarylthio; R4 is independently a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, hydroxy, optionally substituted alkyloxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted cycloalkyloxy, optionally substituted cycloalkenyloxy, mercapto, optionally substituted alkylthio, optionally substituted alkenylthio, optionally substituted alkynylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted alkylsulfonyloxy, optionally substituted cycloalkylthio, optionally substituted cycloalkylsulfinyl, optionally substituted cycloalkylsulfonyl, optionally substituted cycloalkylsulfonyloxy, optionally substituted cycloalkenylthio, optionally substituted cycloalkenylsulfinyl, optionally substituted cycloalkenylsulfonyl, optionally substituted cycloalkenylsulfonyloxy, optionally substituted amino, acyl, optionally substituted alkyloxycarbonyl, optionally substituted alkenyloxycarbonyl, optionally substituted alkynyloxycarbonyl, optionally substituted aryloxycarbonyl, optionally substituted carbamoyl, optionally substituted sulfamoyl, cyano, nitro, optionally substituted aryl, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted arylsulfinyl, optionally substituted arylsulfonyl, optionally substituted arylsulfonyloxy, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heteroarylthio, optionally substituted heteroarylsulfinyl, optionally substituted heteroarylsulfonyl, optionally substituted heteroarylsulfonyloxy or an optionally substituted non-aromatic heterocyclic group; R5 is independently a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted alkyloxy, oxo, optionally substituted aryl, optionally substituted heteroaryl or an optionally substituted non-arom.atic heterocyclic group; M is carbonyl or sulfonyl; Y is a single bond, optionally substituted alkylene optionally containing one or two heteroatom(s), an oxygen atom, a sulfur atom or -N(R6)-; L1, L2 and L3 are independently a single bond, optionally substituted alkylene optionally containing one or two heteroatom(s), optionally substituted alkenylene optionally containing one or two heteroatom(s), optionally substituted alkynylene optionally containing one or two heteroatom(s) or -N(R7)-; R6 and R7 are independently a hydrogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alk^nyl, optionally substituted cycloalkyl, acyl, optionally substituted alkyloxy, optionally substituted aryl, optionally substituted heteroaryl or an optionally substituted non-aromatic heterocyclic group; kis 0, 1, 2, 3 or 4; n is 0, 1 or 2; and q is 0, 1, 2 or 3; provided that a) k is not 0 when the ring B is a 6-membered nitrogen-containing heterocyclic ring containing one or two nitrogen atomfs), and the ring C is a benzene ring, b) the ring C is not an indole ring or an azaindole ring, c) R1 is not carboxy when the ring C is a benzene ring, -L3- is -(O-alkylene)-, and the substituting position of L3 and Y is an ortho-position each other in the ring C, and d) the substituting position of L3 and Y is not a para-position in the ring C when the ring B is a thiazolidine ring and the ring C is a benzene ring; a pharmaceutically acceptable salt or solvate thereof as an active ingredient. 2. A PGD2 receptor antagonist according to claim 1, wherein M is sulfonyl, L1 is a single bond and L2 is a single bond. wherein the ring A is an aromatic carbocyclic ring or an aromatic heterocyclic ring; the ring B is a nitrogen-containing non-aromatic heterocyclic ring or a nitrogen-containing aromatic heterocyclic ring; the ring C is an aromatic carbocyclic ring or an aromatic heterocyclic ring; R1 is hydroxyalkyl, carboxy, alkyloxycarbonyl, optionally substituted carbamoyl, or a carboxy equivalent; R2 is independently a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, hydroxy, optionally substituted alkyloxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted cycloalkyloxy, optionally substituted cycloalkenyloxy, mercapto, optionally substituted alkylthio, optionally substituted alkenylthio, optionally substituted alkynylthio, optionally substituted alkylsulfmyl, optionally substituted alkylsulfonyl, optionally substituted alkylsulfonyloxy, optionally substituted cycloalkylthio, optionally substituted cycloalkylsulfinyl, optionally substituted cycloalkylsulfonyl, optionally substituted cycloalkylsulfonyloxy, optionally substituted cycloalkenylthio, optionally substituted cycloalkenylsulfmyl, optionally substituted cycloalkenylsulfonyl, optionally substituted cycloalkenylsulfonyloxy, optionally substituted amino, acyl, optionally substituted alkyloxycarbonyl, optionally substituted alkenyloxycarbonyl, optionally substituted alkynyloxycarbonyl, optionally substituted aryloxycarbonyl, optionally substituted carbamoyl, optionally substituted sulfamoyl, cyano, nitro, optionally substituted aryl, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted arylsulfinyl, optionally substituted arylsulfonyl, optionally substituted arylsulfonyloxy, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heteroarylthio, optionally substituted heteroarylsulfinyl, optionally substituted heteroarylsulfonyl, optionally substituted heteroarylsulfonyloxy or an optionally substituted non-aromatic heterocyclic group; R3 is a hydrogen atoms, optionally substituted alkyloxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted cycloalkyloxy, optionally substituted cycloalkenyloxy, optionally substituted aryloxy, optionally substituted heteroaryloxy, optionally substituted alkylthio, optionally substituted alkenylthio, optionally substituted alkynylthio, optionally substituted cycloalkylthio, optionally substituted cycloalkenylthio, optionally substituted arylthio or optionally substituted heteroarylthio; R4 is independentiy a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, hydroxy, optionally substituted alkyloxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted cycloalkyloxy, optionally substituted cycloalkenyloxy, mercapto, optionally substituted alkylthio, optionally substituted alkenylthio, optionally substituted alkynylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted alkylsulfonyloxy, optionally substituted cycloalkylthio, optionally substituted cycloalkylsulfinyl, optionally substituted cycloalkylsulfonyl, optionally substituted cycloalkylsulfonyloxy, optionally substituted cycloalkenylthio, optionally substituted cycloalkenylsulfmyl, optionally substituted cycloalkenylsulfonyl, optionally substituted cycloalkenylsulfonyloxy optionally substituted amino, acyl, optionally substituted alkyoxycarbonyl, optionally substituted alkenyloxycarbonyl, optionally substituted alkynyloxycarbonyl, optionally substituted aryloxycarbonyl, optionally' substituted carbamoyl, optionally substituted sulfamoyl, cyano, nitro, optionally substituted aryl, optionally substituted aryloxyl optionally substituted arj^lthio, optionally substituted arylsulfinyl, optionally substituted arylsulfonyl, optionally substituted arylsulfonyloxy, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heteroarylthio, optionally substituted heteroaryisulfinyl, optionally substituted heteroarylsulfonyl, optionally substituted heteroarylsulfonyloxy or an optionally substituted non-aromatic heterocyclic group; R5 is independently a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted alkyloxy, oxo, optionally substituted aryl, optionally substituted heteroaryl or optionally substituted non-aromatic heterocyclic group; M is carbonyl or sulfonyl; Y is a single bond, optionally substituted alkylene optionally containing one or two heteroatom(s), an oxygen atom, a sulfur atom or -N(R6)-; L^, L2 and L^ are independently a single bond, optionally substituted alkylene optionally containing one or two heteroatom(s), optionally substituted alkenylene optionally containing one or two heteroatom(s), optionally substituted alkynylene optionally containing one or two heteroatom(s) or -N(R7)-; R6 and R7 are independently a hydrogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, acyl, optionally substituted alkyloxy, optionally substituted aryl, optionally substituted heteroaryl or an optionally substituted non-aromatic heterocyclic group; k is 0, 1, 2, 3 or 4; n is 0, 1 or 2; and q is 0, 1, 2 or 3; provided that a) k is not 0 when the ring B is a 6-membered nitrogen-containing heterocyclic ring containing one or two nitrogen atom(s), and the ring C is a benzene ring, b) the ring C is not an indole ring or an azaindole ring, c) Y, L1 and L2 are single bonds, the ring B is a piperazine ring and R3 is C2-C4 alkyloxy when the ring C is a benzene ring, -L3- is -(O-alkylene)-, the substituting position of 3 and Y is an ortho-position each other in the ring C and R1 is carboxy, d) the substituting position of L3 and Y is not a para-position in the ring C when the ring B is a thiazolidine ring and the ring C is a benzene ring, and e) the group of the formula of wherein the ring D is a benzene ring, a naphthalene ring, a 2-pyridone ring, a pyridine ring, a benzoxazolone ring, a benzoxadinone ring or a benzimidazole ring; R1 is hydroxyalkyl, carboxy, alkyloxycarbonyl, optionally substituted carbamoyl, or a carboxy equivalent; R2 is independently a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, hydroxy, optionally substituted alkyloxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted cycloalkyloxy, optionally substituted cycloalkenyloxy mercapto, optionally substituted alkylthio, optionally substituted alkenylthio, optionally substituted alkynylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted alkylsulfonyloxy, optionally substituted cycloalkylthio, optionally substituted cycloalkylsulfinyl, optionally substituted cycloalkylsulfonyl, optionally substituted cycloalkylsulfonyloxy, optionally substituted cycloalkenylthio, optionally substituted cycloalkenylsulfinyl, optionally substituted cycloalkenylsulfonyl, optionally substituted cycloalkenylsulfonyloxy, optionally substituted amino, acyl, optionally substituted alkyloxycarbonyl, optionally substituted alkenyloxycarbonyl, optionally substituted alkynyloxycarbonyl, optionally substituted aryloxycarbonyl, optionally substituted carbamoyl, optionally substituted sulfamoyl, cyano, nitro, optionally substituted aryl, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted arylsulfinyl, optionally substituted arylsulfonyl, optionally substituted arylsulfonyloxy, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heteroarylthio, optionally substituted heteroarylsulfinyl, optionadly substituted heteroarylsulfonyl, optionally substituted heteroarylsulfonyloxy or an optionally substituted non-aromatic heterocyclic group; R3 is optionally substituted C1-C6 alkyloxy, optionally substituted C2-C5 alkenyloxy, optionally substituted C2-C6 alkynyloxy, optionally substituted C3-C6 cycloalkyloxy, optionally substituted C3-C6 cycloalkenyloxy, optionally substituted aryloxy, optionally substituted heteroaryloxy, optionally substituted C1-C5 alkylthio, optionally substituted C2-C6 alkenylthio, optionally substituted C2-C6 alkynylthio, optionally substituted C3-C6 cycloalkylthio, optionally substituted C3-C6 cycloalkenylthio, optionally substituted arylthio or optionally substituted heteroarylthio; R4 is independently a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, hydroxy, optionally substituted alkyloxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted cycloalkyloxy, optionally substituted cycloalkenyloxy, mercapto, optionally substituted alkylthio, optionally substituted alkenydthio, optionally substituted alkynylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted alkylsulfonyloxy, optionally substituted cycloalkylthio, optionally substituted cycloalkylsulfinyl, optionally substituted cycloalkylsulfonyl, optionally substituted cycloalkylsulfonyloxy optionally substituted cycloalkenylthio, optionally substituted cycloalkenylsulfinyl, optionally substituted cycloalkenylsulfonyl, optionally substituted cycloalkenylsulfonyloxy, optionally substituted amino, acyl, optionally substituted alkyloxycarbonyl, optionally substituted alkenyloxycarbonyl, optionally substituted alkynyloxycarbonyl, optionally substituted aryloxycarbonyl, optionally substituted carbamoyl, optionally substituted sulfamoyl, cyano, nitro, optionally substituted aryl, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted arylsulfinyl, optionally substituted arylsulfonyl, optionally substituted arylsulfonyloxy, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heteroarylthio, optionally substituted heteroarylsulfinyl, optionally substituted heteroarylsulfonyl, optionally substituted heteroarylsulfonyloxy or optionally substituted non-aromatic heterocyclic group; R5 is independently a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted alkyloxy, oxo, optionally substituted aryl, optionally substituted heteroaryl or an optionally substituted non-aromatic heterocyclic group; M is carbonyl or sulfonyl; L3 is independently a single bond, optionally substituted alkylene optionally containing one or two heteroatom(s), optionally substituted alkenylene optionally containing one or two heteroatom(s), optionally substituted alkynylene optionally containing one or two heteroatom(s) or -N(R'^)-; R*^ is hydrogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, acyl, optionally substituted alkyloxy, optionally substituted aryl, optionally substituted heteroaryl or an optionally substituted non-aromatic heterocyclic group; Y is a single bond or optionally substituted alkylene optionally containing one or two heteroatom(s); Z is CH, C(R4) or N; n is 0, 1 or 2; p s 1, 2, 3 or 4; and q is 0, 1, 2 or 3; provided that R1 is not carboxy when the ring D is a benzene ring, -L3- is -(O-alkylene)-, and the substituting position of L3 and Y is an ortho-position in the ring D; a pharmaceutically acceptable salt or hydrate thereof, 8. A compound according to claim 7, wherein R1 is carboxy and -L3- is -(O- optionally substituted alkylene)-; a pharmaceutically acceptable salt or hydrate thereof. 9. A compound according to claim 7, wherein the ring D is a benzene ring or a pyridine ring; a pharmaceutically acceptable salt or hydrate thereof, 10. A compound according to claim 7, wherein R3 is optionally substituted C1-C6 alkyloxy or optionally substituted C1-C5 alkylthio; a pharmaceutically acceptable salt or hydrate thereof. 11. A compound according to claim 7, wherein M is sulfonyl; a pharmaceutically acceptable salt or hydrate thereof. 12. A compound according to claim 7, wherein Y is a single bond; a pharmaceutically acceptable salt or hydrate thereof. 13. A compound according to claim 7, wherein R2 is a halogen atom, optionally substituted alkyl, optionally substituted alkyloxy, optionally substituted amino, optionally substituted carbamoyl, optionally substituted aryl, optionally substituted heteroaryl or a non-aromatic heterocyclic ring, and p is 1 or 2; a pharmaceutically acceptable salt or hydrate thereof. 14. A compound according to claim 7, wherein R2 is a halogen atom, optionally substituted amino, optionally substituted carbamoyl, optionally substituted aryl, optionally substituted heteroaryl or a non-aromatic heterocyclic ring, and p is 1 or 2; a pharmaceutically acceptable salt or hydrate thereof. R1 is hydroxyalkyl, carboxy, alkyloxycarbonyl, optionally substituted carbamoyl, or a carboxy equivalent; R2 is independently a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl; optionally substituted cycloalkenyl, hydroxy, optionally substituted alkyloxy, optionally substituted alkenyloy, optionally substituted alkynyloxy, optionally substituted cycloalkyloxy, optionally substituted cycloalkenyloxy, mercapto, optionally substituted alkylthio, optionally substituted alkenylthio, optionally substituted alkynylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted alkylsulfonyloxy, optionally substituted cycloalkylthio, optionally substituted cycloalkylsulfmyl, optionally substituted cycloalkylsulfonyl, optionally substituted cycloalkylsulfonyloxy, optionally substituted cycloalkenylthio, optionally substituted cycloalkenylsulfinyl, optionally substituted cycloalkenylsulfonyl, optionally substituted cycloalkenylsulfonyloxy, optionally substituted amino, acyl, optionally substituted alkyloxycarbonyl, optionally substituted alkenyloxycarbonyl, optionally substituted alkynyloxycarbonyl, optionally substituted aryloxycarbonyl, optionally substituted carbamoyl, optionally substituted sulfamoyl, cyano, nitro, optionally substituted aryl, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted arylsulfinyl, optionally substituted arylsulfonyl, optionally substituted arylsulfonyloxy, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heteroarylthio, optionally substituted heteroarylsulfinyl, optionally substituted heteroarylsulfonyl, optionally substituted heteroarylsulfonyloxy or an optionally substituted non-aromatic heterocyclic group; R3 is optionally substituted C1-C6 alkyloxy, optionally substituted C2-C6 alkenyloxy, optionally substituted C2-C6 alkynyloxy, optionally substituted C3-C6 cycloalkyloxy, optionally substituted C3-C5 cycloalkenyloxy, optionally substituted aryloxy, optionally substituted heteroaryloxy, optionally substituted C1-C6 alkylthio, optionally substituted C2-C6 alkenylthio, optionally substituted C2-C6 alkynylthio, optionally substituted C3-C6 cycloalkylthio, optionally substituted C3-C6 cycloalkenylthio, optionally substituted arylthio or optionally substituted heteroarylthio; R'^ is independently a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycioalkenyl, hydroxy, optionally substituted alkyloxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted cycloalkyloxy, optionally substituted cycloalkenyloxy, mercapto, optionally substituted alkylthio, optionally substituted alkenylthio, optionally substituted alkynylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted alkylsulfonyloxy, optionally substituted cycloalkylthio, optionally substituted cycloalkylsulfmyl, optionally substituted cycloalkylsulfonyl, optionally substituted cycloalkylsulfonyloxy, optionally substituted cycloalkenylthio, optionally substituted cycloalkenylsulfinyl, optionally substituted cycloalkenylsulfonyl, optionally substituted cycloalkenylsulfonyloxy, optionally substituted amino, acyl, optionally substituted alkyloxycarbonyl, optionally substituted alkenyloxycarbonyl, optionally substituted alkynyloxycarbonyl, optionally substituted aryloxycarbonyl, optionally substituted carbamoyl, optionally substituted sulfamoyl, cyano, nitro, optionally substituted aryl, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted arylsulfinyl, optionally substituted arylsulfonyl, optionally substituted arylsulfonyloxy, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heteroarylthio, optionally substituted heteroarylsulfinyl, optionally substituted heteroarylsulfonyl, optionally substituted heteroarylsulfonyloxy or an optionally substituted non-aromatic heterocyclic group; R5 is independently a halogen atom, optionally substituted alkyl, optionally substitxited alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted alkyloxy, oxo, optionally substituted aryl, optionally substituted heteroaryl or an optionally substituted non-aromatic heterocyclic group; M is carbonyl or sulfonyl; L3 is independently a single bond, optionally substituted alkylene optionally containing one or two heteroatom(s), optionally substituted alkenylene optionally containing one or two heteroatom(s), optionally substituted alkynylene optionally containing one or two heteroatom(s) or -N(R7)-; R7 is hydrogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, acyl, optionally substituted alkyloxy, optionally substituted aryl, optionally substituted heteroaryl or an optionally substituted non-aromatic heterocyclic group, Y is a single bond or optionally substituted alkylene optionally containing one or two heteroatom(s); Z is CH, C(R4) or N; n is 0, 1 or 2; p is 1, 2, 3 or 4; and q is 0, 1, 2 or 3; provided that a) R1 is not carboxy when the ring D is a benzene ring, -L3- is -(O-alkylene)-, and the substituting position of L3 and Y is 18. A compound according to claim 17, wherein R1 is carboxy and -L3- is - (O-optionally substituted alkylene)-; a pharmaceutically acceptable salt or hydrate thereof, 19. A compound according to claim 17, wherein the ring D is a benzene ring or a pyridine ring; a pharmaceutically acceptable salt or hydrate thereof. 20. A compound according to claim 17, wherein R^ is optionally substituted C1-C6 alkyloxy or optionally substituted C1-C6 alkylthio; a pharmaceutically acceptable salt or hydrate thereof. 21. A compound according to claim 17, wherein M is sulfonyl; a pharmaceutically acceptable salt or hydrate thereof. 22. A compound according to claim 17, wherein Y is a single bond; a phannaceutically acceptable salt or hydrate thereof. 23. A compound according to claim 17, wherein R2 is a halogen atom, optionally substituted alkyl, optionally substituted alkylojqy, optionally substituted amino, optionally substituted carbamoyl, optionally substituted aryl, optionally substituted heteroaryl or a non-aromatic heterocyclic ring, and p is 1 or 2; a pharmaceutically acceptable salt or hydrate thereof. 24. A compound according to claim 17, wherein R2 is a halogen atom, optionally substituted amino, optionally substituted carbamoyl, optionally substituted aryl, optionally substituted heteroaxyl or a non-aromatic heterocyclic ring, and p is 1 or 2; a pharmaceutically acceptable salt or hydrate thereof. 25. A compound according to claim 17, wherein R4 is a halogen atom, optionally substituted alkyl, optionally substituted alkyloxy, and q is 0 or 1; a pharmaceutically acceptable salt or hydrate thereof. 26. A compound according to any of claim 17-25, wherein the substituting position between Y and L3 is a meta-position in the ring D; a pharmaceutically acceptable salt or hydrate thereof. 27. A pharmaceutical com.position comprising a compound according to any of claim 5-26, a pharmaceutically acceptable salt or hydrate thereof as an active ingredient. 28 A pharmaceutical composition of claim 27, which is a DP receptor antagonist. 29. A pharmaceutical composition of claim 27, which is a therapeutic agent for allergy. 30. A pharmaceutical composition of claim 29, wherein the therapeutic agent for allergy is a therapeutic agent for asthma. 31. A method for treating a disease related to DP receptor characterized by administration of the compound of any of claims 5-26, pharmaceutically acceptable salt or solvate thereof. 32. A method according to claim 31, wherein the disease related to DP receptor is asthma, 33. Use of the compound of any of claims 5-26, pharmaceutically acceptable salt or solvate thereof in the manufacturing of a therapeutic agent for treating a disease related to DP receptor. 34. Use of the compound of claim 32, pharmaceutically acceptable salt or solvate thereof, wherein the disease related to DP receptor is asthma wherein the ring D is a benzene ring, a naphthalene ring, a 2-pyridone ring, a pyridine ring, a benzoxazolone ring, a benzoxadinone ring or a benzimidazole ring; R1 is hydroxyalkyl, carboxy, alkyloxycarbonyl, optionally substituted carbamoyl, or a carboxy equivalent; R2 is independently a hydrogen atoms, a halogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, hydroxy, optionally substituted alkyloxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted cycloalkyloxy, optionally substituted cycloalkenyloxy, mercapto, optionally substituted alkylthio, optionally substituted alkenylthio, optionally substituted alkynylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted alkylsulfonyloxy, optionally substituted cycloalkylthio, optionally substituted cycloalkylsulfmyl, optionally substituted cycloalkylsulfonyl, optionally substituted cycloalkylsulfonyloxy, optionally substituted cycloalkenylthio, optionally substituted cycloalkenylsulfmyl, optionally substituted cycloalkenylsulfonyl, optionally substituted cycloalkenylsulfonyloxy, optionally substituted amino, acyl, optionally substituted alkyloxycarbonyl, optionally substituted alkenyloxycarbonyl, optionally substituted alkynyloxycarbonyl, optionally substituted aryloxycarbonyl, optionally substituted carbamoyl, optionally substituted sulfamoyl, cyano, nitro, optionally substituted aryl, optionally substituted aryloxy, optionally substituted arylthio, optionally substituted arylsulfinyl, optionally substituted arylsulfonyl, optionally substituted arylsulfonyloxy, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heteroarylthio, optionally substituted heteroarylsulfinyl, optionally substituted heteroarylsulfonyl, optionally substituted heteroarylsulfonyloxy or an optionally substituted non-aromatic heterocyclic group; R8 is a halogen atom, trifluoromethanesulfonyloxy or piperazino; L3 is independently a single bond, optionally substituted alkylene optionally containing one or two heteroatom(s), optionally substituted alkenylene optionally containing one or two heteroatom(s), optionally substituted alkynylene optionally containing one or two heteroatom(s) or -N(R7)-; R7 is independently a hydrogen atom, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, acyl, optionally substituted alkyloxy, optionally substituted aryl, optionally substituted heteroaryl or an optionally substituted non-aromatic heterocyclic group; and p is 1, 2, 3 or 4; provided that the substituting position of the piperidino group and L3 each other is not an ortho-position in the ring D when the ring D is a benzene ring and -L3- is -(0-alkylene)-; a pharmaceutically acceptable salt or hydrate thereof. 35. A compound according to claim 35, wherein the ring D is a benzene ring and Rs is a halogen atom; a pharmaceutically acceptable salt or hydrate thereof. 37. A compound according to claim 35, wherein the ring D is a benzene ring and R8 is piperazino; a pharmaceutically acceptable salt or hydrate thereof. 38. A compound according to any of claim 35-37, wherein R1 is carboxy or alkyloxycarbonyl and -L3- is -(O-methylene)-; a pharmaceutically acceptable salt or hydrate thereof. 39. A compound according to any of claim 35-38, wherein R2 is a halogen atom, optionally substituted amino, optionally substituted carbamoyl, optionally substituted aryl, optionally substituted heteroaryl, an optionally substituted non-aromatic heterocyclic ring, and p is 1 or 2; a pharmaceutically acceptable salt or hydrate thereof. 40. A compound according to any of claim 35-39, wherein the substituting position between R8 and L3 in the ring D is a meta-position; a pharmaceutically acceptable salt or hydrate thereof. |
|---|
| Patent Number | 272488 | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Indian Patent Application Number | 1485/CHENP/2008 | ||||||||||||||||||
| PG Journal Number | 15/2016 | ||||||||||||||||||
| Publication Date | 08-Apr-2016 | ||||||||||||||||||
| Grant Date | 04-Apr-2016 | ||||||||||||||||||
| Date of Filing | 26-Mar-2008 | ||||||||||||||||||
| Name of Patentee | SHIONOGI & CO., LTD. | ||||||||||||||||||
| Applicant Address | 1-8, DOSHOMACHI 3-CHOME, CHUO-KU, OSAKA-SHI, OSAKA 541-0045, JAPAN | ||||||||||||||||||
Inventors:
|
|||||||||||||||||||
| PCT International Classification Number | C07D 207/48 | ||||||||||||||||||
| PCT International Application Number | PCT/JP06/318917 | ||||||||||||||||||
| PCT International Filing date | 2006-09-25 | ||||||||||||||||||
PCT Conventions:
|
|||||||||||||||||||